AXIM Biotechnologies (AXIM) 10-K/A 19 Apr 22 2021 FY Annual report (amended) Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Apr. 12, 2022
Cover [Abstract]
Entity Registrant Name	AXIM Biotechnologies, Inc.
Entity Central Index Key	0001514946
Document Type	10-K/A
Amendment Flag	true
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		152,001,782
Entity Public Float		$ 34,848,485
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-54296
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	27-4029386
Entity Interactive Data Current	Yes
Auditor Firm Id	587
Entity Address Address Line 1	6191 Cornerstone Court
Entity Address Address Line 2	E, Suite 114
Security 12g Title	Common stock, $0.0001 par value
Entity Address City Or Town	San Diego
Auditor Location	New York, New York
Entity Address Postal Zip Code	92121
City Area Code	858
Local Phone Number	923-4422
Entity Address Address Description	Address of principal executive offices
Auditor Name	RBSM, LLP
Icfr Auditor Attestation Flag	false
Amendment Description	The sole purpose of this Amendment No. 1 to the Annual Report on Form 10-K (the “Form 10-K”) for the period ended December 31, 2020, is to furnish Exhibit 101 to the Form 10-K in accordance with Rule 405 of Regulation S-T.  Exhibit 101 to the Form 10-K provides the financial statements and related notes from the Form 10-K formatted in XBRL (eXtensible Business Reporting Language).  No other changes have been made to the Form 10-K. This Amendment No. 1 to the Form 10-K speaks as of the original filing date of the Form 10-K, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-K.  Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
Entity Address State Or Province	CA

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 452,963	$ 457,181
Prepaid expenses	163,561	255,923
Other Current Assets	20,089
Total current assets	636,613	713,104
Property and equipment, net of accumulated depreciation	116,810	104,094
Other Assets:
Notes receivable- related party	104,268	103,242
Goodwill	0	2,458,233
Research in progress	0	7,800,000
Intangible Asset 510k License and Patents-Eye Care Division, net	4,383,873	0
Security deposit	5,000	5,000
Operating lease right-of-use asset	76,871	130,722
Total other assets	4,570,012	10,497,197
TOTAL ASSETS	5,323,435	11,314,395
Current liabilities:
Accounts payable and accrued liabilities	909,458	1,073,142
Lease liability obligations (see Note 16)	56,871	53,851
Due to shareholder	180	180
Due to first insurance funding	32,873	25,369
Promissory note (including accrued interest of $38,960 and $19,507, respectively)(see note 9)	454,693	343,725
Convertible note payable (including accrued interest of $16,919 and $0, respectively) (see note 12)	1,126,919	0
Total current liabilities	2,580,994	1,496,267
Long-term liabilities:
Deferred tax liability	0	2,340,000
Convertible note payable (including accrued interest of $209,684 and $236,148, respectively) net of unamortized debt discount of $605,640 and $843,673, respectively(see note 12)	761,604	1,676,788
Convertible note payable - related party (including accrued interest of $299,037 and $158,648, respectively)	4,299,037	4,158,648
Lease liability obligations	20,000	76,871
Total long-term liabilities	5,080,641	8,252,307
TOTAL LIABILITIES	7,661,635	9,748,574
STOCKHOLDERS' DEFICIT
Common stock, $0.0001 par value, 300,000,000 shares authorized, 138,099,981 and 125,327,579 shares issued and outstanding, respectively	13,811	12,533
Additional paid in capital	51,000,166	43,201,186
Common stock to be issued	4,530,000	201,974
Accumulated deficit	(57,882,227)	(41,849,922)
TOTAL STOCKHOLDERS' DEFICIT	(2,338,200)	1,565,821
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	5,323,435	11,314,395
Convertible Preferred Stock Series B
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, 5,000,000 shares authorized;	0	0
Convertible Preferred Stock Series C
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, 5,000,000 shares authorized;	$ 50	$ 50

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Interest Payable, Current	$ 16,919	$ 0
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares, Issued	138,099,981	125,327,579
Common Stock, Shares, Outstanding	138,099,981	125,327,579
Unamortized debt discount	$ 605,640	$ 843,673
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	500,000	500,000
Preferred Stock, Shares Issued	500,000	500,000
Preferred Stock, Shares Outstanding	0	0
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	500,000	500,000
Preferred Stock, Shares Issued	500,000	500,000
Preferred Stock, Shares Outstanding	500,000	500,000
Promissory note - related party
Interest Payable, Current	$ 40,475	$ 19,507
Convertible note payable
Interest Payable, Current	192,765	236,148
Unamortized debt discount	605,640	843,673
Convertible note payable - related party
Interest Payable, Current	$ 299,037	$ 158,648

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED BALANCE SHEETS
Revenues	$ 60,460	$ 0
Operating Expenses:
Research and development expenses	284,869	426,708
Selling, general and administrative	5,668,450	4,506,289
Depreciation and amortization	2,115,687	16,001
Impairment Loss	5,966,452
Total operating expenses from continuing operations	14,035,458	4,948,998
Gain (Loss) from continuing operations	(13,974,998)	(4,948,998)
Other (income) expenses:
Interest income	(1,026)	(675)
Income from grants from government	(279,981)	(115,899)
Unrealized loss (gain) on marketable securities	0	104,705
Realized loss (gain) on marketable securities	0	109,040
Loss on extinguishment/conversion of debt	1,587,027	923,605
Amortization of note discount	238,033	86,059
Financing costs	257,466	0
Interest expense	247,792	234,754
Total other (income) expenses	2,049,311	1,341,589
Loss before provision of income tax	(16,024,309)	(6,290,587)
Provision for income tax	0	0
Loss from continuing operations	(16,024,309)	(6,290,587)
Loss from discontinued operations	(7,996)	(119,293)
NET INCOME (LOSS)	(16,032,305)	(6,409,880)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (16,032,305)	$ (6,409,880)
Earnings per share from continuing operations Basic	$ (0.12)	$ (0.06)
Earnings per share from continuing operations Diluted	(0.12)	(0.06)
Earnings per share from discontinued operationsBasic	0	0
Earnings per share from discontinued operationsDiluted	0	0
Earnings per shareBasic	(0.12)	(0.06)
Earnings per shareDiluted	$ (0.12)	$ (0.06)
Weighted average common shares outstanding - basic and diluted	131,539,920	110,386,386

Consolidated Statement of Stock

Consolidated Statement of Stockholders Deficit - USD ($)	Total	Common Stock	Preferred Stock	Series A, Preferred Stock	Series B, Preferred Stock	Series C, Preferred Stock	Common Stock To Be Issued	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2019		64,854,539			500,000	500,000
Balance, amount at Dec. 31, 2019	$ (6,760,396)	$ 6,486	$ 0	$ 0	$ 50	$ 50	$ 50,000	$ 28,623,060	$ (35,440,042)
Common stock to be issued for Note receivable and True-up adjustment	201,974	$ 0	0	0	0	0	201,974	0	0
Common stock issued against common stock to be issued received in PY, shares		250,000
Common stock issued against common stock to be issued received in PY, amount	0	$ 25	0	0	0	0	(50,000)	49,975	0
Common stock issued for services, shares		1,436,782
Common stock issued for services, amount	666,190	$ 143	0	0	0	0	0	666,047	0
Common stock issued for severance, shares		922,486
Common stock issued for severance, amount	480,000	$ 93	0	0	0	0	0	479,907	0
Common stock issued for cash, shares		17,292,751
Common stock issued for cash, amount	3,309,130	$ 1,729	0	0	0	0	0	3,307,401	0
Subscription price adjustment	(609,835)	0	0	0	0	0	0	(609,835)	0
Beneficial conversion feature on the convertible note	190,000	$ 0	0	0	0	0	0	190,000	0
Common stock issued for acquisition, shares		54,000,000
Common stock issued for acquisition, amount	7,506,000	$ 5,400	0	0	0	0	0	7,500,600	0
Retired common stock, shares		(18,570,356)
Retired common stock, amount	(1,857)	$ (1,857)	0	0	$ 0	0	0	0	0
Series B preferred stock retirement, shares					(500,000)
Series B preferred stock retirement, amount	(50)	$ 0	0	0	$ (50)	0	0	0	0
Convertible note and accrued interest converted to common stock, shares		5,141,377
Convertible note and accrued interest converted to common stock, amount	51,414	$ 514	0	0	0	0	0	50,900	0
Stock based compensation - stock options	1,947,745	0	0	0	0	0	0	1,947,745	0
Loss on conversion of convertible note	823,497	0	0	0	0	0	0	823,497	0
Loss on extinguishment of debt	171,889	0	0	0	0	0	0	171,889	0
Net loss	(6,409,880)	$ 0	0	0	0	$ 0	0	0	(6,409,880)
Loss on extinguishment of debt	923,604
Balance, shares at Dec. 31, 2020		125,327,579				500,000
Balance, amount at Dec. 31, 2020	1,565,821	$ 12,533	0	0	0	$ 50	201,974	43,201,186	(41,849,922)
Common stock issued against common stock to be issued received in PY, shares		108,965
Common stock issued against common stock to be issued received in PY, amount	0	$ 11					(66,974)	66,963
Common stock issued for cash, shares		4,304,328
Common stock issued for cash, amount	1,252,000	$ 430						1,251,570
Common stock issued for acquisition, amount	4,270,000						4,270,000
Convertible note and accrued interest converted to common stock, shares		4,372,903
Convertible note and accrued interest converted to common stock, amount	1,221,120	$ 438						1,220,682
Net loss	(16,032,305)								(16,032,305)
Common stock issued for severance payable of discontinued operation, shares		379,463
Common stock issued for severance payable of discontinued operation, amount	225,001	$ 38						224,963
Common stock issued for cash against S-1 agreement, shares		762,400
Common stock issued for cash against S-1 agreement, amount	358,537	$ 76						358,461
Loss on extinguishment of debt	1,587,027							1,587,027
Common stock issued for services, shares		2,529,905
Common stock issued for services, amount	1,888,403	$ 253						1,888,150
Common stock issued for financing cost, shares		118,000
Common stock issued for financing cost, amount	57,466	$ 12						57,454
Common stock issued on cashless option exercise, shares		196,438
Common stock issued on cashless option exercise, amount	0	$ 20						(20)
Common stock to be issued for cash	25,000						25,000
Common stock to be issued for services	100,000						100,000
Stock based compensation options	1,143,730							1,143,730
Balance, shares at Dec. 31, 2021		138,099,981				500,000
Balance, amount at Dec. 31, 2021	$ (2,338,200)	$ 13,811	$ 0	$ 0	$ 0	$ 50	$ 4,530,000	$ 51,000,166	$ (57,882,227)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,032,305)	$ (6,409,880)
Less: Loss from discontinued operations	(7,996)	(119,293)
Loss from continuing operations	(16,024,309)	(6,290,587)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	27,779	16,001
Stock based compensation	1,143,730	2,311,935
Amortization of prepaid expenses	376,936	253,376
Amortization of debt discount	238,033	86,059
Common Stock Issued For Financing Cost	57,466
Common stock issued for services	1,888,391
Common Stock To be issued for Services	100,000
Amortization (Impairment) Of Intangible Assets	2,087,908	0
Loss On Extinguishment of Debt	1,587,027	923,604
Unrealized (gain) loss on marketable securities	0	104,705
Realized (gain) loss on marketable securities	0	109,040
Amortization Of Debt Issuance Cost	100,000	0
Loss on impairment of Intangible Assets	5,966,452	0
Changes in operating assets & liabilities:
Increase (decrease) in interest receivable	(1,026)	(675)
Increase (decrease) in prepaid expenses	(284,574)	(53,585)
Increase (decrease) in accounts payable and accrued expenses	277,507	532,245
(Increase) Decrease in Inventory	(20,089)
Decrease in security deposits		7,785
Net cash provided by (used in) operating activities from continuing operations	(2,478,769)	(2,000,097)
Net cash provided by (used in) operating activities from discontinued operations	(7,996)	(1,215,602)
Net cash provided by (used in) operating activities	$ (2,486,765)	(3,215,699)
CASH FLOW FROM INVESTING ACTIVITIES:
Acquisition Of Patents	(10,000)
Proceeds from Sales of Marketable Securities	$ 0	0
Cash acquired in acquisition		79,814
Increase in property and equipment	(40,495)	(97,324)
Net cash provided by (used in) investing activities from continuing operations	(50,495)	(17,510)
Net cash provided by (used in) investing activities from discontinued operations	0	27,490
Net cash provided by (used in) investing activities	(50,495)	9,980
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds From Convertible Note	1,010,000	0
Common stock issued under registration statement on Form S-3		1,510,500
Repayment Of Promissory Note	(120,000)
Proceeds From Common Stock Under S-!	358,538
Proceeds From Common stock to be issued under Stock Purchase agreement	25,000
Common stock issued under SPA	1,252,000	1,798,630
Repayment of First Insurance Funding	7,504	(92,860)
Net cash provided by (used in) continuing financing activities	2,533,042	3,216,270
Net cash provided by (used in) discontinued financing activities		(65,000)
Net cash provided by (used in) financing activities	2,533,042	3,151,270
Net increase (decrease) in cash and cash equivalents	(4,218)	(54,449)
Cash and cash equivalents at beginning of period	457,181	511,630
Cash and cash equivalents at end of period	452,963	457,181
CASH PAID DURING THE PERIOD FOR:
Interest	0	0
Income taxes - net of tax refund	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES
Common stock issued against common stock to be issued	66,974	50,000
Account receivable against conversion of debt and interest	0	0
Common stock issued against CS subscription	0	0
Common stock issued for services recorded as prepaid expense	0	302,000
Common stock issued for severance	225,000	480,000
Shares issued for acquisition of Sapphire Biotechnology	0	7,506,000
Deferred tax liability accounted for as a result of Sapphire Biotech Acquisition	0	2,340,000
Assets acquired and liability assumed as a result of Sapphire Biotech Acquisition	0	525,365
BCF related to discount on conversion	0	190,000
Common stock issued for note receivable	0	135,000
Adoption of lease obligation and ROU asset	0	164,910
Common stock retired	0	1,907
Convertible note issued against subscription price adjustment	0	609,835
Convertible note converted to common stock	1,221,119	51,414
Assets acquired as a result of Sapphire Biotech Acquisition	0	33,319
Prepaid insurance paid through first insurance funding		76,108
Common Stock Issued on Cashless exercise of Options	20
Acquisition Of Patents against Notes Payable And Accounts Payable	240,000
Common Stock To be Issued For Acquisition	4,270,000
Others	$ 0	$ 71,782

ORGANIZATION

ORGANIZATION	12 Months Ended
	Dec. 31, 2021
ORGANIZATION
ORGANIZATION	NOTE 1: ORGANIZATION The Company was originally incorporated in Nevada on November 18, 2010, as Axim International Inc. On July 24, 2014, the Company changed its name to AXIM Biotechnologies, Inc. to better reflect its business operations. The Company’s principal executive office is located at 6191 Cornerstone Court E suite 114 San Diego Ca 92121. On August 7, 2014, the Company formed a wholly owned Nevada subsidiary named Axim Holdings, Inc. This subsidiary will be used to help facilitate the anticipated activities planned by the Company. On May 11, 2015 the Company acquired a 100% interest in CanChew License Company a Nevada incorporated licensing Company, through the exchange of 5,826,706 shares of its common stock. In October 2017 the company formed a wholly owned subsidiary in the Netherlands for purposes of holding pharmaceutical licenses as required by the Netherlands regulations and laws. On October 16, 2018, the Company formed a wholly owned disregarded entity Marina Street, LLC as part of improvement of internal control over cash management and bank activities. On March 17, 2020, the Company acquired Sapphire Biotech, Inc., (“Sapphire’) which is research and Development Company that has a mission to improve global cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis. Sapphire is also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. Additionally, with the onset of the COVID-19 pandemic, the Company decided to begin creating COVID-19 rapid diagnostic tools, including multiple first-in-class COVID-19 neutralizing antibody tests and other innovations. Sapphire’s operations are located in the Greater San Diego Area. Company Developments – Divesture of Cannabis Related Assets On May 6, 2020 (the “Effective Date”), AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), entered into an Agreement (the “Separation Agreement”) by and among the Company, CanChew License Company (“CanCo”), CanChew Biotechnologies, LLC (“CanChew”), Medical Marijuana, Inc., Dr. George A. Anastassov (“Dr. Anastassov”), Dr. Philip A. Van Damme (“Dr. Van Damme”), Lekhram Changoer (“Mr. Changoer”), Sanammad Foundation, Netherlands and Sanammad Foundation, US (collectively, the “Sanammad Parties”), pursuant to which, among other matters as described herein, Drs. Anastassov and Van Damme and Mr. Changoer resigned as members of the Company’s Board of Directors. Pursuant to the Separation Agreement, the Company transferred and assigned to an entity designated by Dr. Anastassov all of the Company’s cannabis-related intellectual property other than the inventions and discoveries described in that certain cannabis-related patent application filed by the Company’s wholly-owned subsidiary, Sapphire Biotech, Inc. (water-soluble cannabinoid molecules). The Company also transferred 100% of its interest in CanCo and CanChew to an entity designated by Dr. Anastassov. In consideration for the transfers set forth above, any and all indebtedness owed by the Company to CanChew, totaling approximately $2.61 million, was satisfied and paid in its entirety. In addition, in consideration for the payment by the Company of $65,000, the Company purchased 100% of the issued and outstanding shares of Series B Preferred Stock held by the Sanammad Parties. Such shares shall be retired to treasury of the Company. The Sanammad Parties also agreed to forfeit and assign back to treasury, for no consideration, a total of 18,570,356 shares of the Company’s common stock. COVID-19 impact and related risks The ongoing global outbreak of COVID-19, and the various attempts throughout the world to contain it, have created significant volatility, uncertainty and disruption. In response to government directives and guidelines, health care advisories and employee and other concerns, A number of the Company’s employees have had to work remotely from home and those on site have had to follow the Company’s social distance guidelines, which could impact their productivity. COVID-19 could also disrupt the Company’s operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of management and other employees who cannot effectively work remotely but who elect not to come to work due to the illness affecting others in the Company’s office or laboratory facilities, or due to quarantines. Because of COVID-19, travel, visits, and in-person meetings related to The Company’s business have been severely curtailed or canceled and the Company has instead used on-line or virtual meetings to meet with potential customers and others. In addition to operational adjustments, the consequences of the COVID-19 pandemic have led to uncertainties related to The Company’s business growth and ability to forecast the demand for its diagnostic testing and resulting revenues. The full extent to which the COVID-19 pandemic and the various responses to it might impact The Company’s business, operations and financial results will depend on numerous evolving factors that are not subject to accurate prediction and that are beyond The Company’s control.

ACQUISITION OF SAPPHIRE BIOTECH

ACQUISITION OF SAPPHIRE BIOTECH, INC.	12 Months Ended
	Dec. 31, 2021
ACQUISITION OF SAPPHIRE BIOTECH, INC.
ACQUISITION OF SAPPHIRE BIOTECH, INC.	NOTE 2: ACQUISITION OF SAPPHIRE BIOTECH, INC. On March 17, 2020, the Company entered into a Share Exchange Agreement (“Agreement”) with Sapphire Biotech, Inc., a Delaware corporation (“Sapphire”) and all of the Sapphire stockholders (collectively, the “Sapphire Stockholders”). Following the closing of the transaction, Sapphire will become a wholly owned subsidiary of AXIM. Under the terms of the Agreement, the Company: (i) acquired 100% of Sapphire’s outstanding capital (consisting of 100,000,000 shares of common stock and zero (0) shares of Preferred Stock); and (ii) assume all of the outstanding debt of Sapphire. The outstanding debt includes two (2) convertible notes in the principal amounts of $310,000 and $190,000. Pursuant to the terms of the Share Exchange Agreement, the Company acquired 100% of the issued and outstanding shares of Sapphire by means of a share exchange with the Sapphire Stockholders in exchange for 54,000,000 newly issued shares of the common stock of AXIM (the “Share Exchange”). As a result of the Share Exchange, Sapphire became a 100% owned subsidiary of AXIM, which on a going forward basis will result in consolidated financial reporting by AXIM to include the results of Sapphire. The closing of the Share Exchange occurred concurrently with entry into the Share Exchange Agreement (the “Closing”). In March 2020, the Company acquired Sapphire Biotech, Inc., a biotechnology company focusing on improving cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis. The Company issued 54,000,000 shares of common stock with a total fair value of $7,506,000 and assumed net liabilities of $412,233 (resulting in a total acquisition cost of $7,918,233), in exchange for all outstanding shares of Sapphire Biotech, Inc. The Company accounted for the acquisition using the acquisition method of accounting for business combinations. On the acquisition date, the Company performed a preliminary allocation of the purchase price to include the tangible assets acquired and the liabilities assumed with the remainder of the purchase price allocated to patents pending approval, in-process research and development (IPR&D) and goodwill. The Company incurred $6,000 of acquisition-related costs, which will be recorded as expense after the evaluation work been completed. In addition, the Company recorded an estimated deferred tax liability on the assets acquired, except for goodwill for which deferred taxes are not applicable. The Company completed the valuation of the intangible assets acquired in the Sapphire Biotech, Inc. transaction by September 2020. Pursuant to the valuation, the Company determined that the patents continue to be expanded and chose to subsume the patents within the IPR&D balance. In management’s judgment, the amount assigned to IPR&D represents the amount the Company would reasonably expect to pay an unrelated party for each project included in the technology. Based on the final valuation, the remaining excess purchase price has been allocated to goodwill. The aggregate purchase price of $7,918,233 consisted of common stock valued at $7,506,000 and the net liabilities assumed of $412,233. The value of the $7,506,000 of common shares issued was determined based on the closing price of the Company’s common shares at the acquisition date. The following table summarizes the consideration paid for Sapphire and the estimated amounts of the assets acquired and liabilities assumed recognized at the acquisition date. Consideration: Cash and cash equivalents $ 79,814 Property and equipment, net 20,533 In process R&D 7,800,000 Goodwill 2,458,233 Security deposit 12,785 Total asset acquired $ 10,371,365 Accrued expenses and other current liabilities $ 5,767 Deferred taxes liability 2,340,000 Notes Payable including convertible and discount on conversion 519,598 Total liabilities assumed $ 2,865,365 Net assets acquired $ 7,506,000 Of the $7,918,233, assets were recorded in the amount of $113,132 and liabilities were assumed of $525,365, $7,800,000 was assigned to IPR&D and $118,233 was allocated to goodwill and $2,340,000 was calculated as the deferred tax liability on the assets acquired, which amount was included in goodwill at the date of acquisition in accordance with accounting requirements. The fair value of acquired IPR&D was determined using the income approach, based on the likelihood of success of products reaching final development and commercialization. The fair value of acquired IPR&D was capitalized as of the Closing Date and is subsequently accounted for as an indefinite-lived intangible asset until completion or abandonment of the associated research and development efforts. Accordingly, during the development period after the Closing Date, this asset will be amortized over a period of 36 months. The $2,458,233 of goodwill is not expected to be deductible for tax purposes. The effective settlement of receivable/payable between the Company and Sapphire deemed to be not material, which was recorded as gain on intercompany transaction in P&L. Disclosure of Pro Forma Information The following (unaudited) pro forma consolidated results of operations have been prepared as if the acquisition of Sapphire Biotech, Inc. had occurred at January 1, 2020: For twelve months ended December 31, 2021 December 31, 2020 Revenues $ - $ - Net loss from continuing operations $ (16,024,309 ) $ (6,290,906 ) Net income (loss) from discontinued operations $ (7,996 ) $ (119,293 ) Net loss per share—Basic and Diluted $ (0.12 ) $ (0.06 ) The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisition been consummated as of that time, nor is it intended to be a projection of future results. During the twelve months ended December 31, 2021 Sapphire had no revenue transactions. As of December 31, 2021 the asset was deemed impaired and was written off resulting in an impairment loss of $5,966,452.

ACQUISITION OF INTELLECTUAL PRO

ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC, LLC.	12 Months Ended
	Dec. 31, 2021
ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC, LLC.
ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC, LLC.	NOTE 3: ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC, LLC. AXIM entered into two substantially contemporaneous transactions to acquire patents and 510(K) Licenses from Advanced Tear Diagnostics, LLC (the “Seller”) (collectively, the “Asset Acquisition”) for a total amount of $4,520,000. The first transaction occurred on July 29, 2021, in which AXIM purchased five patents (the “Patents”) from the Seller for $250,000 (which includes assuming and paying $30,000 of the Seller’s liabilities). The bulk of the purchase price ($210,000) was in a note that requires seven equal monthly payments of $30,000, which payment started on September 3, 2021. The second transaction occurred on August 26, 2021, in which AXIM purchased certain eye disease diagnostic technology, which consisted of a 510(K) license for Lactoferrin, a biomarker for dry eye disease and a 510(K) license for IgE, a biomarker for allergic ocular reaction (collectively, the “510(K) Licenses”). The purchase price for the 510(K) Licenses was $4,270,000, which price was paid by issuing to the Seller 7 million shares of AXIM restricted common stock. Together, the Patents and the 510(K) Licenses constitute the acquired technology asset (the “Technology Asset”), which for accounting purposes, are considered one unit of account. We are amortizing the Technology Asset ratably over the 11.54 average remaining life of the Patents. In accordance with FASB’s requirements for accounting for business combinations (FASB Accounting Standards Codification, Topic 805, Business Combinations

BASIS OF PRESENTATION

BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2021
BASIS OF PRESENTATION
BASIS OF PRESENTATION	NOTE 4: BASIS OF PRESENTATION The consolidated financial statements of AXIM Biotechnologies, Inc. (formerly Axim International, Inc.) as of December 31, 2021, and 2020 have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”). Principles of Consolidation The consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiaries Axim Holdings, Inc., Marina Street LLC, Axim Biotechnologies (the Netherland Company) and Sapphire Biotech, Inc. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated upon consolidation.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2021
GOING CONCERN
GOING CONCERN	NOTE 5: GOING CONCERN The Company’s consolidated financial statements have been presented assuming that the Company will continue as a going concern. As shown in the consolidated financial statements, the Company has negative working capital of $1,944,381 and has an accumulated deficit of $57,882,227, has cash used in operating activities of continuing operations $2,478,769. The Company extinguished its old debt and entered in debt exchange agreement. On April 16, 2018, the Company entered into a Stock Purchase Agreement and sold 1,945,000 shares of our common stock registered under the Registration Statement on Form S-3 declared effective by the Securities and Exchange Commission on September 14, 2017. On March 11, 2019 the company issued shares in accordance with an SPA dated August 1, 2018 which the amount reduced due to shareholder by $400,000. During the year ended December 31, 2021, the Company raised additional capital of $1,610,538 through Stock Purchase Agreements. This capital provides funds for research, development, and ongoing operations. The Company intends to raise substantial additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. That will raise a doubt about the ability of the Company to continue as a going concern. The consolidated financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	NOTE 6: SIGNIFICANT ACCOUNTING POLICIES Use of estimates Operating lease We lease property under various operating leases which are disclosed on our Balance sheet in accordance with ASC 842 Risks and uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows; ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations. There have been no material changes in the accounting policies from those disclosed in the financial statements and the related notes included in the Form 10-K. Cash equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. As of December 31, 2021, the Company had no cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company had no uninsured balances at December 31, 2021. The Company has never experienced any losses related to these balances. Accounts Receivable It is the Company’s policy to review accounts receivable at least on a monthly basis for conductibility and follow up with customers accordingly. Covid19 has slowed collection as our customers are in a mandated pause. We do not have geographic concentration of customers. Concentrations At December 31, 2021, there was no accounts receivable. For the year ended December 31, 2021, one customer accounted for 21% of total revenue. For the year ended December 31, 2020, two customers accounted for 95% of total revenue. Revenue was all generated from discontinued operations for the twelve months ending December 31, 2021 and 2020. Property and equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. The Company’s property and equipment relating to continuing operations consisted of the following at December 31, 2021 and 2020, respectively, and none related to discontinued operations. December 31, 2021 December 31, 2020 Equipment of continuing operations $ 175,283 $ 134,788 Less: accumulated depreciation $ 58,473 $ 30,694 $ 116,810 $ 104,094 Intangible Assets Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. We conduct an impairment analysis for goodwill annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. We first may assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test included in U.S. GAAP. To the extent our assessment identifies adverse conditions, or if we elect to bypass the qualitative assessment, goodwill is tested using a quantitative impairment test. Impairment of Indefinite-Lived Intangible Assets For indefinite-lived intangible assets such as in-process research and development (IPRD), we conduct an impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist. We first perform a qualitative assessment to determine if it is more likely than not that the carrying amount of each of the in-process research and development assets exceeds its fair value. The qualitative assessment requires the consideration of factors such as recent market transactions, macroeconomic conditions, and changes in projected future cash flows. If we determine it is more likely than not that the fair value is less than its carrying amount of the in-process research and development assets, a quantitative assessment is performed. The quantitative assessment compares the fair value of the in-process research and development assets to its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized for the excess. We elected to perform a quantitative assessment of indefinite-lived intangible assets and determined that the fair value of the goodwill and IPRD related to the Sapphire acquisition was less than its carrying amount and that in-process research and development were fully impaired The Company’s intangible assets relating to continuing operations and discontinued operations consisted of the following at December 31, 2021 and 2020, respectively December 31, December 31, 2021 2020 Goodwill $ - $ 2,458,233 Intellectual Property (IPRD) - 7,800,000 Patents 250,000 - Licenses 4,270,000 - 4,520,000 10,258,233 Less: accumulated amortization 136,127 - $ 4,383,873 $ 10,258,233 Estimated aggregate amortization expense for each of the five succeeding years ending December 31 is as follows: 2022 2023 2024 2025 2026 and thereafter Amortization expense $ 375,500 $ 375,500 $ 375,500 $ 375,500 $ 2,881,873 Amortization expense recorded for the years ended December 31, 2021 and 2020 was $2,087,908 and $0; respectively. The Company recognized and impairment charge of $2,458,233 and $5,848,219 related to Goodwill and IPRD; respectively in 2021. Goodwill and Intangible assets were impaired resulting in a net impairment loss of $5,966,452, resulting from an FDA decision not to approve our COVID test. Revenue Recognition The Company follows the guidance contained in Topic 606 (FASB ASC 606). The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods of services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. All revenue was from operations that were divested. Revenues are recognized when title for goods is transferred; non-refundable fees and proceeds from irrevocable agreements recognized when inflows or other enhancements of assets of the Company are received. Revenues from continuing operations recognized for twelve months ended December 31, 2021 and 2020 amounted to $60,460 and $-0-, respectively. Revenues from discontinued operations recognized for twelve months ended December 31, 2021 and 2020 amounted to $0 and $7,990, respectively. Collaboration Revenue Revenue recognition for collaboration agreements will require significant judgment. The Company’s assessments and estimates are based on contractual terms, historical experience and general industry practice. Revisions in these values or estimations have the effect of increasing or decreasing collaboration revenue in the period of revision. On August 21, 2020, the Company entered into a Distribution, License and Supply Agreement (“License Agreement”) with Empowered Diagnostics, LLC (“Empowered Diagnostics”). The License Agreement provides Empowered Diagnostics with a right to commercialize The company’s products worldwide with the exception of Mexico. Under the License Agreement, the company is responsible for applying for and obtaining necessary regulatory approvals in the US and EU, as well as marketing, sales and distribution of the products. Empowered Diagnostics will pay a transfer price for all licensed products, and upon achievement of certain regulatory and sales milestones, the Company may receive payments from Empowered Diagnostics equal to 8% of the monthly gross revenue. Agreement continues until terminated by mutual consent or uncorrected breach. This agreement with Empowered Diagnostics was terminated in February, 2022 The Company did not recognize any revenue from this agreement, Grant Income In 2021 the Company has received government grants to drive its research and development efforts. Through these government grants, the government has provided funding for the Company to perform research and development activities which will assist in developing its products. The Company believes the government entities funding these grants are interested in the Company advancing its underlying technologies through research activities and not providing incentives for hiring employees or building facilities that would suggest that the grant monies are not for specific research activities. In determining how to classify the monies received under government grants, the Company acknowledges that there is no specific guidance under US GAAP and that the FASB and AICPA have often drawn upon the guidance in IAS 20 for classification. In considering the alternatives provided by IAS 20 for the presentation of these grants in the Company’s financial statements, the Company believes that recognizing the government grant proceeds as a component of other revenue is a better reflection of the economics of the arrangements as the Company earns the funding through the performance of research and development which is not one of the Company’s primary business activities or central to its operations. The Company believes that presenting research and development funding from government grants, as other revenue provides consistency in our financial reporting. The Company also believes that this presentation clearly presents to users of its financial statements in one line the Company’s sources of funding from these grants. The Company notes that there are no contingencies associated with the receipt of or ability to retain the funds under the grant, other than undertaking and performing the related research and development activities. The Company recognizes funds received from contractual research and development services and from government grants as other revenue. These contracts and grants are not considered an ongoing major and central operation of the Company’s business. Our Income from Grants from Government for the years ended December 31, 2021 and 2020, was $279,981 and $115,899 respectively. Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to the customers including buying and transportation costs. Cost of sales all related to discontinued operations. Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in general and administrative expenses. Shipping costs all related to discontinued operations. Fair Value Measurements The Company applies the guidance that is codified under ASC 820-10 related to assets and liabilities recognized or disclosed in the financial statements at fair value on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The Company’s financial instruments are cash and cash equivalents, accounts receivable, accounts payable, notes payable, and long-term debt. The recorded values of cash and cash equivalents and accounts payable approximate their fair values based on their short-term nature. The recorded values of notes payable and long-term debt approximate their fair values, as interest approximates market rates. ASC 820-10 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820-10 requires valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows: Fair Value Hierarchy Inputs to Fair Value Methodology Level 1 Quoted prices in active markets for identical assets or liabilities Level 2 Quoted prices for similar assets or liabilities; quoted markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the financial instrument; inputs other than quoted prices that are observable for the asset or liability; or inputs that are derived principally from, or corroborated by, observable market information Level 3 Pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption is unobservable or when the estimation of fair value requires significant management judgment For the twelve months ended December 31, 2021 and 2020 The Company recorded unrealized gain (loss) on marketable securities of $0 and $(104,705), respectively, and realized gain (loss) on marketable securities of $0 and $(109,040), respectively. The Company had no marketable securities as of December 31, 2021 and 2020. The Company did not have any Level 2 or Level 3 assets or liabilities as of December 31, 2021 and 2020. The fair value of the Company’s convertible promissory notes is estimated based on the current rates offered to the Company for debt of similar terms and maturities. Under this method, the Company’s fair value of convertible debt was not significantly different from the carrying value at December 31, 2021. The Company’s acquired goodwill with a carrying amount of $2,458,233 were written down to zero, resulting in an impairment charge of $2,458,233, which was included in earnings for the period. In-process Research and Development with a carrying amount of $5,848,219 was written down to its implied fair value of zero, resulting in an impairment charge of $5,848,219, which was included in earnings for the period. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities.” Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability. Income Taxes The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. No amounts were accrued for the payment of interest and penalties as of December 31, 2021 and 2020. The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2021 and 2020. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “Cares Act”) was enacted. The CARES Act included loans and grants to certain businesses, and temporary amendments to the Internal Revenue Code which changed net loss carryforward and back provisions and the business interest expenses limitation. Under the CARES Act provisions, the most relevant income tax considerations to Oncocyte relate to the amounts received under the Paycheck Protection Program loan program and the possible forgiveness of those loans by the SBA. On December 21, 2020, the U.S. president has signed into law the “Consolidated Appropriations Act, 2021” which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans can deduct regular business expenses that are paid for with the loan proceeds for federal tax purposes. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company had $0 and $240,769 allowance for doubtful accounts at December 31, 2021 and 2020, respectively and had $0 accounts receivable at December 31, 2021 and $240,769 at December 31, 2020, all was related to discontinued operations. Net Loss per Common Share Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. There were common share equivalents 30,119,877 at December 31, 2021 and 32,556,727 at December 31, 2020. For the year ended December 31, 2021 and 2020 these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share. Stock Based Compensation All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued. The Company accounts for stock options issued to non-employees based on the estimated fair value of the awards using the Black-Scholes option pricing model in accordance with ASC 505-50, Equity-Based Payment to Non-employees Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the twelve months ended December 31, 2021 and 2020 The Company incurred research and development expenses of $284,869 and $426,708 from continuing operations, respectively. For the twelve months ended December 31, 2021 and 2020 the Company incurred research and development expenses of $0 and $377,416 from discontinued operations, respectively. The Company has entered into various agreements with CROs. The Company’s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Recently Issued Accounting Standards Accounting Standards Implemented Since December 31, 2020 ASC Update 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in this Update do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic. That is, accounting for those instruments continues to be subject to the requirements in other Topics. The amendments in this Update do not affect a holder’s accounting for freestanding call options. ASC Update No. 2020-10 In October 2020, the FASB issued ASC Update No. 2020-10, Codification Improvements. Update No. 2020-10 amends a wide variety of Topics in the Codification in order to improve the consistency of the Codification and the application thereof, while leaving Generally Accepted Accounting Principles unchanged. ASC Update No. 2020-06 In August 2020, the FASB issued ASC Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in Update No. 2020-06 simplify the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity’s own equity Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

PREPAID EXPENSES

PREPAID EXPENSES	12 Months Ended
	Dec. 31, 2021
PREPAID EXPENSES
PREPAID EXPENSES	NOTE 7: PREPAID EXPENSES Prepaid expenses consist of the following as of December 31, 2021 and 2020: December 31, December 31, 2021 2020 Prepaid insurance $ 59,116 $ 45,983 Prepaid services 104,445 209,940 $ 163,561 $ 255,923 For the year ended December 31, 2021 and 2020 the Company recognized amortization of prepaid expense and prepaid insurance of $376,936 and $253,376 respectively.

PROMISSORY NOTE

PROMISSORY NOTE	12 Months Ended
	Dec. 31, 2021
PROMISSORY NOTE
PROMISSORY NOTE	NOTE 8: PROMISSORY NOTE On August 8, 2014 the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (the owners of CCB also own a majority of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The original loan was a demand note bearing interest at the rate of 7% per annum, which amount, along with principal, was payable upon demand. The demand note was amended effective January 1, 2015 to reduce the annual interest rate to 3%. All other terms and conditions shall remain in full force and effect. On May 6, 2020 (the “Effective Date”), AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), entered into an Agreement (the “Separation Agreement”). Pursuant to the Separation Agreement, the Company transferred 100% of its interest in CanCo and CanChew to an entity designated by Dr. Anastassov. In consideration for the transfers set forth above, any and all indebtedness owed by the Company to CanChew, totaling approximately $2.61 million, was satisfied and paid in its entirety. For the years ended December 31, 2021 and 2020, the Company recognized interest expense of $0 and $0, respectively on this note all was related to continuing operations. On December 31, 2019, Sapphire Biotech, Inc. had entered into a Debt Exchange Agreement whereas the Company assumed three (3) loans totaling $128,375 of Debt owned by Sapphire Diagnostics, LLC which had an interest rate of 6% per annum. In the same Debt Exchange Agreement, the Company assumed four (4) additional loans made to Sapphire in 2019, which had an interest rate of 6% per annum. All seven (7) loans totaling $310,000, plus the aggregate interest accrued thereon of $14,218 making the face value of the new note $324,218. As of December 31, 2021 and 2020, the principal and accrued interest balances were $363,178 and $343,725 respectively. On July 29, 2021, the Company recorded a $210,000 note payable in conjunction with the acquisition of patents from Advanced Tear Diagnostics LLC. The note balance as of December 31, 2021 is $90,000 with accrued interest of $1,515.

OTHER COMMITMENTS

OTHER COMMITMENTS	12 Months Ended
	Dec. 31, 2021
OTHER COMMITMENTS
OTHER COMMITMENTS	NOTE 9: OTHER COMMITMENTS The Company owes $5,000 to the chairman of the board of the Company for a working capital advance of $5,000 made in May of 2014, all was related to discontinued operations. Under an agreement Mr. Changoer received on March 20, 2018 the Company issued 50,000 restrictive shares of its common stock and recorded $235,000 of compensation expenses in the accompanying consolidated financial statements to account for the issuance of the incentive shares. As of December 31, 2021 and 2020, the total outstanding balance was $20,000 and $60,000 respectively for consulting fees to Mr. Changoer included in accounts payable. On September 25, 2018, the Company amended Independent Director Compensation agreement. Under the agreement in lieu of the share compensation due to independent director of the Company for his annual service ending May 23, Dr. Philip A. Van Damme shall receive cash compensation of $20,000. Started from August 1, 2019 the company has been paying monthly clinical trial fee of $5,000. As of December 31, 2021 and 2020, the total outstanding balance was $-0- and $25,000, respectively included in accounts payable. Effective January 1, 2019 the company entered into a thirty-months consulting agreement with the chairman of the board which pays a monthly consulting fee of $20,000. The company has also been paying a monthly bonus fee of 15,000; this additional fee is on a month-to-month basis at the discretion of management. As of December 31, 2021 and 2020, the total outstanding balance was $40,000 and $225,000 respectively for consulting fees included in accounts payable. On May 6, 2020 (the “Effective Date”), AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), entered into an Agreement (the “Separation Agreement”) by and among the Company, CanChew License Company (“CanCo”), CanChew Biotechnologies, LLC (“CanChew”), Medical Marijuana, Inc., Dr. George A. Anastassov (“Dr. Anastassov”), Dr. Philip A. Van Damme (“Dr. Van Damme”), Lekhram Changoer (“Mr. Changoer”), Sanammad Foundation, Netherlands and Sanammad Foundation, US (collectively, the “Sanammad Parties”), pursuant to which, among other matters as described herein, Drs. Anastassov and Van Damme and Mr. Changoer resigned as members of the Company’s Board of Directors. Pursuant to the Separation Agreement, the Company transferred and assigned to an entity designated by Dr. Anastassov all of the Company’s cannabis-related intellectual property other than the inventions and discoveries described in that certain cannabis-related patent application filed by the Company’s wholly-owned subsidiary, Sapphire Biotech, Inc. (water-soluble cannabinoid molecules). The Company also transferred 100% of its interest in CanCo and CanChew to an entity designated by Dr. Anastassov. In consideration for the transfers set forth above, any and all indebtedness owed by the Company to CanChew, totaling approximately $2.61 million, was satisfied and paid in its entirety. In addition, in consideration for the payment by the Company of $65,000, the Company purchased 100% of the issued and outstanding 500,000 shares of Series B Preferred Stock held by the Sanammad Parties. Such shares shall be retired to treasury of the Company. The Sanammad Parties also agreed to forfeit and assign back to treasury, for no consideration, a total of 18,570,356 shares of the Company’s common stock. In addition, each of Drs. Anastassov and Van Damme and Mr. Changoer have agreed to subject the shares of the Company’s common stock held by each of them to lock-up and leak-out restrictions, as follows: they shall not sell shares for a period of 12 months following the Effective Date and, thereafter, subject to a daily volume limitation of 5%, on an aggregate basis among them. The Company retains the right to prepay the severance obligations to Drs. Anastassov and Mr. Changoer, without penalty. No claims were alleged by the Company against any party, and no claims were alleged against the Company. However, in connection with the transactions described above, the parties entered into a general mutual release of all claims.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2021
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 10: RELATED PARTY TRANSACTIONS Related Party The company has an employment agreement with Catalina Valencia at a rate of $15,000 per month commencing March 17, 2020. The agreement can be terminated with 30 days’ notice by either party The company has a consulting agreement with Glycodots LLC whereby it will provide the services of Dr. Sergei A. Svarovsky at a rate of $15,000 per month commencing March 17, 2020. The agreement can be terminated with 30 days’ notice by either party. Purchase of Promissory Note and Forbearance Agreement Effective May 4, 2020, the Company acquired from TL-66, a California limited liability company (“Seller”), a promissory note issued to Seller by Dr. Anastassov (“Maker”) dated December 1, 2017, with a face value of $350,000 and a remaining balance due of approximately $100,000 (the “Note”). The purchase price for the Note was $100,000 payable by the Company issuing Seller One Million (1,000,000) restricted shares of the Company’s Common Stock. Effective May 6, 2020, the Company and Maker entered into a Forbearance Agreement whereby the Company agreed to forbear from making any collection efforts on the Note for a period of 24 months so long as Maker has not breached the Separation Agreement. Following 24 months, if there has been no breach of the Separation Agreement by Maker, repayment of the Note, including all principal and unpaid interest, will be waived in full. As of May, 4, 2020 the carrying value of the note receivable was $102,567, the value of the common stock to be issued was $135,000, resulting in a loss of $32,433 accounted as loss on debt extinguishment related to discontinued operations. The balance of the Note Receivable as of December 31, 2021 and 2020 is $102,567 and $102,567 excluding interest accrued thereon of $1,701 and $675, respectively.

DUE TO FIRST INSURANCE FUNDING

DUE TO FIRST INSURANCE FUNDING	12 Months Ended
	Dec. 31, 2021
DUE TO FIRST INSURANCE FUNDING
DUE TO FIRST INSURANCE FUNDING	NOTE 11: DUE TO FIRST INSURANCE FUNDING On June 25, 2020, the Company renewed its D&O insurance policy with total premiums, taxes and fees for $93,357. A cash down payment of $18,671 was paid on July 6, 2020. Under the terms of the insurance financing, payments of $8,546, which include interest at the rate of 4.6% per annum, are due each month for nine months commencing on July 25, 2020. On June 25, 2021, the Company renewed its D&O insurance policy with total premiums, taxes and fees for $98,888. A cash down payment of $24,273 was paid on July 7, 2021. Under the terms of the insurance financing, payments of $1,797, which include interest at the rate of 4.420% per annum, are due each month for nine months commencing on July 25, 2021. The total outstanding due to First Insurance Funding as of December 31, 2021 and 2020 is $32,873 and $25,369, respectively.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	12 Months Ended
	Dec. 31, 2021
CONVERTIBLE NOTES PAYABLE
CONVERTIBLE NOTES PAYABLE	NOTE 12: CONVERTIBLE NOTES PAYABLE The following table summarizes convertible note payable of related party as of December 31, 2021 and 2020: December 31, December 31, 2021 2020 Convertible note payable, due on November 1, 2026, interest at 3.5% p.a. $ 4,000,000 $ 4,000,000 Accrued interest 299,037 158,648 Convertible note payable, net $ 4,299,037 $ 4,158,648 The interest on this note is payable bi-annually every May 1 and November 1. On May 1, 2019 the Company paid accrued interest of $60,278. In 2020 the Company was authorized to apply the accounts receivable of $75,074 due from Kannaway towards its accrued interest. On May 1, 2020, the Company agreed to modify its existing convertible note with a principal balance of $4 million, 3.5% interest rate convertible note with the current holder of that note. There were two changes to the existing agreement – (a) the conversion price was reduced from the $1.50 conversion price in the original Note to $0.25 cents in the modified Note and (b) the term of the note was extended from the original maturity date of November 1, 2021, to November 1, 2026. The Company’s stock closed trading on the day of the modification at $0.13 per share. The amendment of this convertible Note was also evaluated under ASC Topic 470-50-40, ”Debt Modifications and Extinguishments.” Based on the guidance, the instruments were determined to be substantially different due to the change in the conversion price being substantial, and debt extinguishment accounting was applied. The fair value of the modified convertible note was not different than the carrying value of the original note as such no extinguishment loss was recorded, The Note prior to the amendment of approximately $4 million, and the fair value of the Note and embedded derivatives after the amendment of approximately $4 million. There were no unamortized debt issuance costs and the debt discount associated with the original 2018 Note. For the years ended December 31, 2021 and 2020, interest expense was $140,389 and $140,389, respectively. As of December 31, 2021 and 2020, the balance of secured convertible note was $4,299,037 and $4,158,648 which included $299,037 and $158,648 accrued interest, respectively. The following table summarizes convertible note payable as of December 31, 2021 and 2020: December 31, December 31, 2021 2020 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. $ 484,478 $ 484,478 Convertible Note Payable, due on October 1, 2022, interest at 6% p.a. 1,110,000 - Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. 500,000 1,000,000 Convertible note payable, due on December 31, 2034, interest at 3% p.a. 190,000 190,000 Convertible note payable, due on July 21, 2032, interest at 3.5% p.a. - 609,835 Accrued interest (The accrued interest and principal are both included in the captions titled “convertible note payable” in the balance sheet) 209,685 236,148 Total 2,494,163 2,520,461 Less: unamortized debt discount/finance premium costs (605,639 ) (843,673 ) Convertible note payable, net $ 1,888,524 $ 1,676,788 On September 16, 2016, we entered into a convertible note purchase agreement (the “Convertible Note Purchase Agreement” or “Agreement”) with a third-party investor. Under the terms of the Convertible Note Purchase Agreement the investor may acquire up to $5,000,000 of convertible notes from the Company. With various closings, under terms acceptable to the Company and the investor as of the time of each closing. Pursuant to the Agreement, on September 16, 2016 the investor provided the Company with $850,000 secured convertible note financing pursuant to four (4) Secured Convertible Promissory Notes (the “Notes”). Each of the Notes matures on October 1, 2029, and pay 3.5% compounded interest paid bi-annually. The Note are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company common stock at a conversion price equal to $0.2201 per share. As of December 31, 2021 and 2020, the balance of secured convertible notes was $573,612 and $556,420, which included $89,134 and $71,942 accrued interest, respectively. On October 20, 2016 a third-party investor provided the Company with $1,000,000 secured convertible note financing pursuant to three (3) Secured Convertible Promissory Notes (the “Notes”). Each of the Notes mature on October 1, 2029 and pay 3.5% compounded interest paid bi-annually. The Notes are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company’s common stock at a fixed conversion price equal of $0.2201 per share. The investor paid cash of $500,000 for one of the Notes and issued to the Company two (2) secured promissory notes of $250,000 each for two (2) Convertible Notes of $250,000 each. The two secured promissory notes issued by the investor (totaling $500,000) as payment for two (2) secured Notes totaling $500,000 mature on February 1, 2017 ($250,000) and March 1, 2017 ($250,000), bear interest at the rate of 1% per annum, are full recourse and additionally secured by 10,486,303 shares of Medical Marijuana, Inc. (Pink Sheets symbol: MJNA) and were valued at $858,828 based upon the closing price of MJNA on October 20, 2016. A debt discount was recorded related to beneficial conversion feature inn connection with this convertible note of $499,318, related to the beneficial conversion feature of the note to be amortized over the life of the note or until the note is converted or repaid. As of December 31, 2021 and 2020, this note has not been converted and the balance of secured convertible notes was $592,915 and $1,148,944, which included $92,215 and $148,944 accrued interest, respectively. On June 7, 2021 the Company converted $500,000 of the Convertible Note with TL-66-LLC along with the accrued interest of $82,707 into 2,647,464 shares of the Company’s common stock at $0.2201 per share which resulted in a loss on extinguishment of debt of $1,535,264. On December 31, 2019, Sapphire Biotech, Inc. entered into a Convertible Note Purchase Agreement whereas the Company issued a convertible note with a face value of $190,000 with a compounding interest rate of 3% per annum, the interest shall be payable annually beginning on December 31, 2020 until the maturity date of December 31, 2034, at which time all principal and interest accrued thereon shall be due and payable. The Convertible Note is secured by substantially all the Company’s tangible and intangible assets. In addition, the Convertible Note includes various non-financial covenants including the Company may not enter into any agreement, arrangement or understanding of any kind that would result in a transaction, or series of transactions, that would result in the sale of 50% or more of the Company’s capital stock without the prior approval of the holder. On March 17, 2020 the Company entered into a Share Exchange Agreement (“Agreement”) with Sapphire Biotech, Inc., a Delaware corporation (“Sapphire”) and all of the Sapphire stockholders (collectively, the “Sapphire Stockholders”). Following the closing of the transaction, Sapphire will become a wholly owned subsidiary of AXIM. Under the terms of the Agreement, the Company intends to assume the convertible notes in the principal amounts of $190,000. After the acquisition, the Convertible Note was able to convert 6,000,000 shares of Axim’s common stock. Upon assumption of the note, the Company recorded a beneficial conversion feature of $190,000. As of December 31, 2021 and 2020, the balance of secured convertible note was $201,416 and $195,716, which included $11,416 and $5,716 accrued interest, respectively. On July 21, 2020 the Company entered into convertible note purchase agreement with Cross & Company, the Company owed to Cross & Company $609,835 of aggregated payments and desired to satisfy the amount due in full by issuing to Cross & Company a convertible promissory note. The convertible note matures on July 21, 2032 and incurred 3.5% compounded interest paid annually. The Note are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company common stock at a conversion price equal to $0.37. Notwithstanding the foregoing, holder shall not be permitted to convert the note, or portion thereof, if such conversion would result in beneficial ownership by holder and its affiliates of more than 4.9% of the debtor’s outstanding common stock as of the date of conversion. The Company determined that that the conversion of the amounts due into a long-term convertible note resulted in a debt extinguishment due to the change in the fair values exceeding 10%. Accordingly, the loss of $823,497 was included in the statement of operations as loss on debt extinguishment. As of December 31, 2021 and 2020, the balance of secured convertible note was $0 and $619,381, which included $0 and $9,546 accrued interest respectively. The note was converted to 1,725,439 shares which included accrued interest at time of conversion of $28,578 common stock on November 24, 2021 at which time the company recorded loss on conversion expense of $51,763. On September 27, 2021 the Company entered into convertible note purchase agreement with GS Capital LLC in the amount of $1,110,000. The note had an original issue discount of $100,000, bridge financing fees of $100,000 and legal costs of $30.000, which were amortized to financing cost on the issuance of note. It bears interest at a rate of 6% and matures September 29,2022. The note is convertible to free trading shares six months after issuance at a conversion price of $0.25 per share subject to a 10 day look back period at time of conversion if the stock is trading at less than $0.25 for more than 5 days then the conversion price will be a 30 percent discount to the average of the two lowest closing prices within the 10 day look back period. As of December 31, 2021 and 2020, the balance of this convertible note was $1,126,919 and $0, which included $16,919 and $0 accrued interest; respectively. The note was paid off in February 2022. During the years ended December 31, 2021 and 2020, the Company amortized the debt discount on all the notes of $238,033 and $86,059, respectively. As of December 31, 2021 and 2020, unamortized debt discount was $605,640 and $843,673, respectively.

STOCK INCENTIVE PLAN

STOCK INCENTIVE PLAN	12 Months Ended
	Dec. 31, 2021
STOCK INCENTIVE PLAN
STOCK INCENTIVE PLAN	NOTE 13: STOCK INCENTIVE PLAN On May 29, 2015 the Company adopted its 2015 Stock Incentive Plan. Under the Plan the Company may issue up to 10,000,000 S-8 shares to officers, employees, directors or consultants for services rendered to the Company or its affiliates or to incentivize such parties to continue to render services. S-8 shares are registered immediately upon the filing of the Plan and are unrestricted shares that are free-trading upon issuance. On May 20, 2021 the board consent increased the issue up to 20,000,000 shares. As of December 31, 2021 and 2020, there were 8,094,046 and 9,806,000 shares available for issuance under the Plan. On May 13, 2020, Alim Seit-Nebi the Chief Technology Officer and Co-Founder of Sapphire Biotechnology was granted the options to purchase 1 million shares of Axim common stock under the plan at the exercise price of $0.126 per share. One third of the options will vest six months from the date of grant, one third of the options will vest one year from the date of grant, and the remaining one third of the options will vest two years from the date of grant. On May 13, 2020, Dr. Douglas Lake the Chief Clinical Officer and Co-Founder of Sapphire Biotechnology was granted the options to purchase 2 million shares of Axim common stock under the plan at the exercise price of $0.126 per share. One third of the options will vest six months from the date of grant, one third of the options will vest one year from the date of grant, and the remaining one third of the options will vest two years from the date of grant. On May 13, 2020, Timothy R, Scott the Director of Axim Biotechnology was granted the options to purchase 0.5 million shares of Axim common stock under the plan at the exercise price of $0.126 per share. One third of the options vested immediately, one third of the options will vest six months from the date of grant, and the remaining one third of the options will vest twelve months from the date of grant. On May 13, 2020, Robert Cunningham the Director of Axim Biotechnology was granted the options to purchase 0.5 million shares of Axim common stock under the plan at the exercise price of $0.126 per share. One third of the options vested immediately, one third of the options will vest six months from the date of grant, and the remaining one third of the options will vest twelve months from the date of grant. On May 13, 2020, Maurico Bellora the Director of Axim Biotechnology was granted the options to purchase 0.5 million shares of Axim common stock under the plan at the purchase price of $0.126 per share. One third of the options vested immediately, one third of the options will vest six months from the date of grant, and the remaining one third of the options will vest twelve months from the date of grant. On September 10, 2020, Noel C. Gillespie the Senior Patent Attorney of Axim Biotechnology was granted the options to purchase 0.5 million shares of Axim common stock under the plan at the purchase price of $0.61 per share. One third of the options vested immediately, one third of the options will vest one year from the date of grant, and the remaining one third of the options will vest two years from the date of grant. On August 2, 2021, Bijan Pedram the Senior Scientific of Sapphire Biotechnology was granted the options to purchase 0.1 million shares of Axim common stock under the plan at the purchase price of $0.67 per share. 25% of the Option shares will be vested upon the one anniversary of the vesting commencement day and the balance of the option shares will be vested of thirty-six (36) successive equal monthly in the first anniversary of the vesting commencement day. On August 17, 2021, Jeff Busby the Senior Vice president of Sales of Axim Biotechnology was granted the options to purchase 1 million of shares of Axim common stock under the plan at the purchase price of $0.60 per share. 25% of the Option shares will be vested upon the one anniversary of the vesting commencement day, 25% of the Option shares will be vested upon the two anniversaries of the vesting commencement day, 25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day. On September 1, 2021, Laura M. Periman Medical advisory board member of Axim Biotechnology was granted the options to purchase 0.1 million of shares of Axim common stock under the plan at the purchase price of $0.64 per share. 50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day. On September 4, 2021, Kelly K. Nichols Medical advisory Board member of Axim Biotechnology was granted the options to purchase 0.1 million of shares of Axim common stock under the plan at the purchase price of $0.62 per share. 50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day. On September 8, 2021, Joseph Tauber the Ophthalmic Chief Medical Officer (CMO) of Axim Biotechnology was granted the options to purchase 1 million of shares of Axim common stock under the plan at the purchase price of $0.622 per share. 25% of the Option shares will be vested upon the one anniversary of the vesting commencement day, 25% of the Option shares will be vested upon the two anniversaries of the vesting commencement day, 25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day. For the years ended December 31, 2021 and 2020 the Company recorded compensation expense of $1,143,730 and $1,947,745 respectively.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	12 Months Ended
	Dec. 31, 2021
STOCKHOLDERS' DEFICIT
STOCKHOLDERS DEFICIT	NOTE 14: STOCKHOLDERS’ DEFICIT Preferred Stock The Company has authorized 5,000,000 shares of preferred stock, with a par value of $0.0001 per share. Of the 5,000,000 authorized preferred shares, 4,000,000 are undesignated “blank check” preferred stock. The Company may issue such preferred shares and designate the rights, privileges and preferences of such shares at the time of designation and issuance. As of December 31, 2021, and 2020 there are -0- and -0- shares of undesignated preferred shares issued and outstanding, respectively. There are zero shares issued and outstanding of Series A and Series B Preferred stock as of December 31, 2021. Series C Convertible Preferred Stock On August 17, 2016 the Company designated up to 500,000 shares of a new Series C Convertible Preferred Stock (Series C Preferred Stock). The holders of the Series C Preferred are entitled to elect four members to the Company’s board of directors and are entitled to cast 100 votes per share on all other matters presented to the shareholders for a vote. Each share of Series C Convertible Preferred is convertible into one share of the Company’s common stock. The Series C Convertible Preferred designation contains a number of protective and restrictive covenants that restrict the Company from taking a number of actions without the prior approval of the holders of the Series C Preferred or the unanimous vote of all four Series C Directors. If at any time there are four Series C Directors, one such director must be independent as that term is defined in the Series C designation. Any challenge to the independence of a Series C Director is a right conferred only upon the holders of the Series B Convertible Preferred Stock and may only be made by the holders of the Series B Convertible Preferred Stock. On August 18, 2016 the Company issued all 500,000 shares of its newly designated Series C Preferred Stock to MJNA Investment Holdings, LLC in exchange for cash of $65,000. As the holders of the Series C Preferred Stock, MJNA Investment Holdings, LLC has designated Dr. Timothy R. Scott, John W. Huemoeller II, Robert Cunningham and Blake Schroeder as their four Series C Directors. On February 20, 2019, MJNA Investment Holdings LLC (“Seller”) sold its 500,000 shares of AXIM Biotechnologies, Inc.’s, a Nevada corporation (the “Company”) Series C Preferred Stock to Juniper & Ivy Corporation, a Nevada corporation (“Purchaser”) for a purchase price of $500,000 (the “Purchase Price”) pursuant to a Preferred Stock Purchase Agreement (the “Purchase Agreement”). Payment of the Purchase Price was made as follows (i) a $65,000 payment made by check payable to Seller, which Purchaser borrowed from an unrelated third-party and which has no recourse against the Series C Preferred Stock or assets of Purchaser (the “Loan”), and (ii) the issuance by Purchaser to Seller of a promissory note, face value, $435,000, which has no recourse against the Series C Preferred Stock or assets of Purchaser (the “Note”). The Company’s Chief Executive Officer John W. Huemoeller II is the President of Purchaser. Mr. Huemoeller provided a personal guaranty for the Loan and the Note. The holders of the Series C Preferred Stock are entitled to elect four members to the Company’s Board of Directors and are entitled to cast 100 votes per share on all other matters presented to the shareholders for a vote. As a result of this transaction, a change in control has occurred. Effective April 2, 2019, Blake N. Schroeder resigned as a member of the Company’s Board of Directors. Mr. Schroeder’s resignation was not because of any disagreements with the Company on matters relating to its operations, policies and practices. On April 3, 2019 pursuant to the Company’s Amended and Restated Bylaws, the holder of the Company’s Series C Preferred Stock appointed Mauricio Javier Gatto-Bellora to fill the director seat vacated by the resignation of Mr. Schroeder. On July 21, 2020 pursuant to the Company’s Amended and Restated Bylaws, the holder of the Company’s Series C Preferred Stock appointed Peter O’Rourke to fill one of the vacant positions on board created by the resignations of Dr. George Anastassov, Lekhram Changoer, and Dr. Philip Van Damme. Common Stock The Company has authorized 300,000,000 shares of common stock, with a par value of $0.0001 per share. As of December 31, 2021, and 2020, the Company had 138,099,981 and 125,327,579 shares of common stock issued and outstanding, respectively. 2021 Transactions: Common Stock On December 13, 2021 the company entered into an agreement where it will issue $100,000 of stock in exchange for services to be rendered under a consulting agreement, currently shown as stock to be issued. On November 7, 2021 the company issued 1,725,439 of its shares in settlement of a debt of 638,412 including accrued interest of $28,578. During the period between May 14, 2021 and December 31, 2021 the Company issued total 500,000 shares valued $129,274 pursuant to the Company’s Registration Statement on Form S-1. The Company received $129,274 in cash. On October 12, 2021 the Company issued 118,000 shares to GS capital valued at $57,466 pursuant to services rendered in obtaining financing. On October 18, 2021 the company issued 175,000 shares of its common stock valued at $52,500 pursuant to a stock purchase agreement. During the year ended December 31, 2021, the company issued 196,438 shares of common stock upon the exercise of 300,000 options at an exercise price of $0.126 a share. This exercise was performed on a cashless basis. On July 29, 2021 the Company issued 122,000 restricted shares of its common stock to third party valued at $50,000 pursuant to the stock purchase agreement. The cash was received in 2021. During August and September 2021 the Company issued 1,060,715 commons shares and warrants to purchase 1,060,715 shares of common stock at an exercise price of $0.60 for gross cash proceeds of $297,000 pursuant to various Warrant Stock purchase agreements. The cash was received in the third quarter ending 2021. Warrants are exercisable within a 3-year period from issuance. During July and September 2021 the company issued 1,415,554 restricted shares of its common stock valued at $1,111,900 to third parties for certain services, recorded as consulting fees. In September 2021 the company issued 262,400 restricted shares of its common stock valued at $129,724 pursuant to S-1 Agreement to third party for cash, recorded as subscription receivable. Pursuant to its purchase of Advanced Tear Diagnostics, LLC the company has recorded 7,000,000 shares of its common stock to be issued valued at $4,270,000. On May 14, 2021, The Company entered into the Equity Purchase Agreement with Cross, pursuant to which we have the right to “put,” or sell, up to $10,000,000 worth of shares of our common stock to Cross. As provided in the Equity Purchase Agreement, we may require Cross to purchase shares of our common stock from time to time by delivering a put notice to Cross specifying the total number of shares to be purchased (such number of shares multiplied by the purchase price described below, the “Investment Amount”); provided there must be a minimum of ten trading days between delivery of each put notice. We may determine the Investment Amount, provided that such amount may not be more than 500% of the average daily trading volume in dollar amount for our common stock during the five trading days preceding the date on which we deliver the applicable put notice, unless waived by Cross in its sole discretion. Additionally, such amount may not be lower than $10,000 or higher than $1,000,000. Cross will have no obligation to purchase shares under the Equity Line to the extent that such purchase would cause Cross to own more than 4.99% of our issued and outstanding shares of common stock. In June 2021 the company issued 500,000 restricted shares of its common stock valued at $332,500 pursuant to S-1 Agreement to third party recorded as subscription receivable. Actual proceeds were $228,812. The difference of $103,688 was adjusted to additional paid in capital and was calculated in accordance with the S-1 agreement. During April, May and June 2021 the company issued 2,647,464 restricted shares of its common stock valued at $2,117,971 pursuant to conversion of convertible note and accrued interest of $582,707 (Note 12) with a loss on extinguishment of debt $1,535,264. During April, May and June 2021 the Company issued 1,234,113 shares for cash of gross proceed of $402,500 pursuant to various Warrant Stock purchase agreements. The cash was received in the second quarter ending 2021. Out of these 519,828 shares of common stock valued at $152,500 was adjusted with common stock to be issued of prior period. The company also issued warrants to purchase 175,000 shares of common stock at an exercise price of $0.75 and 714,285 shares of common stock at an exercise price of $0.80. Warrants are exercisable within a 3 year period from issuance. During April, May and June 2021 the company issued 1,114,351 restricted shares of its common stock valued at $792,389 to third parties for certain services, recorded as consulting fees. During March 2021 the Company issued 1,712,500 shares for cash of gross $434,000 pursuant to various Stock purchase agreements. The cash was received in the first quarter ending 2021. The company also issued warrants to purchase 900,000 shares of common stock at an exercise price of $0.75. Warrants are exercisable within a 3 year period from issuance. Company paid finders fees of $20,000 in cash during this period for capital raise and will also issue shares equaling $16,000 in market value, which was issued during the year ended December 31, 2021. On March 18, 2021 the company issued 488,428 restricted shares of its common stock valued at $291,974 to third parties for certain services, recorded as consulting fees. Out of these 108,965 shares of common stock valued at $66,974 was adjusted with common stock to be issued of prior year. 2020 Transactions: During the period between January 1, 2020 and December 31, 2020 the Company issued total 17,292,751 shares valued $3,309,130 pursuant to the Company’s Registration Statement on Form S-3. The Company received $3,309,130 in cash. On January 13, 2020 the Company issued 250,000 restricted shares of its common stock to third party valued at $50,000, which were carried on the books as stock to be issued. On January 23, 2020 and February 26, 2020 the Company issued 600,000, and 62,839 restricted shares of its common stock to third party valued at $262,500, and $25,000 pursuant to the stock purchase agreement for certain services, recorded as advertising and promotion expense and License, permits & Patents, respectively. On March 17, 2020 the company acquired 100% of the issued and outstanding shares of Sapphire by means of a share exchange with the Sapphire Stockholders in exchange for 54,000,000 restricted shares of its common stock at valued $7,506,000. On April 21, 2020 the Company issued 1,176,470 restricted shares of its common stock to third party valued at $100,000 pursuant to the stock purchase agreement. The cash was received in 2020. On May 6, 2020, the Company entered into an agreement with Sanammad Foundation, the Sanammad Parties agreed to forfeit and assign back to treasury, for no consideration, a total of 18,570,356 shares of the Company’s common stock, for which the fair value was $2,562,709, however for accounting purpose this transaction recording at par value adjustment to additional paid in capital. This transaction is related to the divesture of the previous operations to Sanammad. On May 22, 2020 the Company issued 190,810 and 286,215 S-8 shares valued at $60,000 and $90,000 pursuant to the Company’s Registration Statement on Form S-8 for severance fees. On June 10, 2020 and June 24, 2020 the Company issued 2,173,913 and 625,000 restricted shares of its common stock to third party valued at $500,000 and $100,000 pursuant to the stock purchase agreement. The cash was received in 2020, respectively. On July 1, 2020 the Company issued 185,185 and 370,370 restricted shares of its common stock to third party valued at $25,000 and $50,000 pursuant to the stock purchase agreement. The cash was received in 2020, respectively. On July 2, 2020 and July 9, 2020 the Company issued 714,285 and 1,785,714 restricted shares of its common stock to third party valued at $100,000 and $250,000 pursuant to the stock purchase agreement. The cash was received in 2020, respectively. On July 10, 2020 the Company issued 5,141,377 restricted shares of its common stock in exchange for the conversion of $51,414 of a convertible note payable, which included $6,414 in interest. On July 10, 2020 the Company issued 142,857 and 357,153 restricted shares of its common stock to third party valued at $20,000 and $50,000 pursuant to the stock purchase agreement. The cash was received in 2020, respectively. On July 10, 2020 the Company issued 250,000 and 107,143 restricted shares of its common stock to third party valued at $35,000 and $15,000 pursuant to the stock purchase agreement. The cash was received in 2020, respectively. On July 14, 2020 the Company issued 200,000 restricted shares of its common stock to third party valued at $23,630 pursuant to the stock purchase agreement. The cash was received in 2020, respectively. On July 21, 2020 the Company entered into convertible note purchase agreement with Cross & Company, the Company owed to Cross & Company $609,835 of aggregated True-Up payments due to subscription price adjustment and desired to satisfy the amount due in full by issuing to Cross & Company a convertible promissory note (see note 12). On July 22, 2020 the Company issued 65,359 and 130,719 restricted shares of its common stock to third party valued at $20,000 and $40,000 pursuant to the stock purchase agreement. The cash was received in 2020, respectively. On July 22, 2020 the Company issued 163,398 and 326,797 restricted shares of its common stock to third party valued at $50,000 and $100,000 pursuant to the stock purchase agreement. The cash was received in 2020, respectively. On July 22, 2020 the Company issued 816,993 and 65,359 restricted shares of its common stock to third party valued at $250,000 and $20,000 pursuant to the stock purchase agreement. The cash was received in 2020, respectively. On July 24, 2020 359,524 shares for the purchase of prepaid marketing expenses valued at $302,000. On August 4, 2020 the Company issued 141,243 restricted shares of its common stock to third party valued at $50,000 pursuant to the stock purchase agreement. The cash was received in 2020. On August 6, 2020 the Company issued 148,166 and 166,686 S-8 shares valued at $120,000 and $135,000 pursuant to the Company’s Registration Statement on Form S-8 for severance fees. On August 12, 2020 the Company issued 414,419 restricted shares of its common stock to third party valued at $76,690 pursuant to the stock purchase agreement for certain services, recorded as commission fees. On December 7, 2020 the Company issued 130,609 S-8 shares of its common stock to third party value at $75,000 pursuant to the Company’s Registration Statement on Form S-8 for severance fees.

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2021
STOCK OPTIONS AND WARRANTS
STOCK OPTIONS AND WARRANTS	NOTE 15: STOCK OPTIONS AND WARRANTS Options to purchase common stock are granted at the discretion of the Board of Directors, a committee thereof or, subject to defined limitations, an executive officer of the Company to whom such authority has been delegated. Options granted to date generally have a contractual life of ten years. The stock option activity for years ended December 31, 2021 and 2020 is as follows: Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2019 2,000,000 $ 0.75 Granted 8,300,000 0.27 Exercised - - Expired or canceled - - Outstanding at December 31, 2020 10,300,000 0.36 Granted 2,960,715 0.60 Exercised (300,000 ) 0.35 Expired or canceled (2,000,000 ) 0.75 Outstanding at December 31, 2021 10,960,715 $ 0.37 The following table summarizes the changes in options outstanding, option exercisability and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at December 31, 2021 and 2020: 2,000,000 options issued to John Huemoeller were canceled to allow for issuances to other employees. As of December 31, 2021 Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.36 10,960,715 8.5 $ 0.37 8,094,046 $ 0.37 As of December 31, 2020 Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.36 10,300,000 9.8 $ 0.36 7,466,662 $ 0.36 The Company determined the value of share-based compensation for options vested using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: December 31, December 31, 2021 2020 Expected life (years) 10 10 Risk-free interest rate (%) 1.74 0.61 Expected volatility (%) 190 230 Dividend yield (%) - - Weighted average fair value of shares at grant date $ 1.74 $ 0.61 For the years ended December 31, 2021 and 2020 stock-based compensation expense related to vested options was $1,143,730 and $1,947,745 respectively. Warrants The following table summarizes warrant activity during the year ended December 31, 2021: Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2020 - $ - Granted 2,850,000 0.71 Forfeited/Cancelled - - Exercised - - Outstanding at December 31, 2021 2,850,000 $ 0.71 All outstanding warrants are exercisable at December 31, 2021 and there was no unrecognized stock-based compensation expense related to warrants. During the year ended December 31, 2020 there was no warrant activity.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	12 Months Ended
	Dec. 31, 2021
DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS	NOTE 16: DISCONTINUED OPERATIONS During May 2020 the Company decided to discontinue most of its operating activities pursuant to the Separation Agreement entered into by and among the Company, CanChew License Company (“CanCo”), CanChew Biotechnologies, LLC (“CanChew”), Medical Marijuana, Inc., Dr. George A. Anastassov (“Dr. Anastassov”), Dr. Philip A. Van Damme (“Dr. Van Damme”), Lekhram Changoer (“Mr. Changoer”), Sanammad Foundation, Netherlands and Sanammad Foundation, US (collectively, the “Sanammad Parties”). (see Note 1) Pursuant to the terms of the Purchase Agreement dated as of May 6, 2020, Sanammad Parties agreed to acquire from the Company substantially all of its assets and its wholly-owned subsidiaries and to assume certain liabilities and its wholly-owned subsidiaries. Sanammad Parties agreed to pay a purchase price of $2,609,100 reflected in amount due Canchew were deemed paid in full. The sale, which was completed on May 6, 2020, did not include the Company’s cash and certain other excluded assets and liabilities. The assets sold and liabilities transferred in the transaction were the sole revenue generating assets of the Company. The results of operations associated with the assets sold have been reclassified into discontinued operations for periods prior to the completion of the transaction. The following is a summary of assets and liabilities sold, stock retired and gain recognized, in connection with the sale of assets to Sanammad parties: Other current assets $ 5,000 Total current assets $ 510,017 Intangible assets, net of amortization $ 47,375 Total asset $ 562,392 Notes payable $ 880,000 Accounts payable and accrued expenses $ 210,640 Due to Canchew $ 1,526,603 Stock retired $ 1,857 Total liabilities and equity $ 2,619,100 The gain on sale of assets was reported during the period was determined as follows: Loss on sale of assets $ (562,392 ) Gain on sale of liabilities $ 2,619,100 Net gain from sale of assets and liabilities $ 2,056,708 The resulting gain from the sale will be fully offset by existing net operating loss carryforwards available to the Company. For the years ended December 31, 2021 and 2020 the Company recognized interest expense of $-0- and $-0-, respectively. As of December 31, 2021 and 2020, the Company has nil asset and liabilities of the discontinued operations in the unaudited condensed consolidated balance sheet in accordance with the provision of ASC 205-20. Loss from Discontinued Operations The sale of the majority of the assets and liabilities related to the Sanammad parties represents a strategic shift in the Company’s business. For this reason, the results of operations related to the assets and liabilities held for sale for all periods are classified as discontinued operations. The following is a summary of the results of operations related to the assets and liabilities held for sale (discontinued operations) for the years ended December 31, 2021 and 2020: December 31, 2021 December 31, 2020 Net sales $ - $ 5,097 Total expenses $ (7,996 ) $ (2,016,742 ) Gain from sale of asset and liability $ - $ 2,056,708 Other (loss) income $ - $ (164,356 ) (Loss) income from discontinued operations $ (7,996 ) $ (119,293 ) The following is a summary of net cash provided by or used in operating activities, investing activities and financing activities for the assets and liabilities held for sale (discontinued operations) for the years ended December 31, 2021 and 2020: December 31, 2021 December 31, 2020 Net (loss) income from discontinued operations $ (7,996 ) $ 119,293 ) Adjustment of non-cash activities - 726,748 Decrease in accounts receivable - Increase in inventory - Increase in accounts payable and accrued expenses - (1,823,057 ) Net cash provided by (used in) operating activities $ (7,996 ) $ (1,215,602 ) Net cash provided by (used in) investing activities $ - $ 27,490 Net cash provided by (used in) financing activities $ - $ (65,000 )

COMMITMENT AND CONTINGENCIES

COMMITMENT AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
COMMITMENT AND CONTINGENCIES
COMMITMENT AND CONTINGENCIES	NOTE 17: COMMITMENT AND CONTINGENCIES On January 2, 2019 the Company entered into the term of Executive’s employment agreement, at a base salary of $10,000 per month with John W. Huemoeller II to serve as its Chief Executive Officer. The Company and Executive acknowledge and agree that Executive’s employment hereunder shall at all times be “at will,” which means that either Executive may resign at any time for any reason or for no reason, and that the Company may terminate Executive’s employment at any time for any reason or for no reason, in either case, subject to the applicable provisions of this Agreement. In further consideration for Executive’s services and subject to the approval of the Board, Executive will be granted an option to purchase 2,000,000 shares of the Company’s common stock (the “Option Shares”). The option will be subject to the terms and conditions applicable to stock options granted under the Company’s 2015 Stock Incentive Plan, as amended from time to time (the “Plan”), and as described in the Plan and the stock option agreement, which Executive will be required to sign. 50% of the Option Shares shall vest on the date of grant and the remaining 50% of the Option Shares shall vest on the 12- month anniversary of the grant date, subject to Executive’s continued employment by the Company. The exercise price per share will be equal to the fair market value per share on the date of grant, as determined by the last closing price of the Company’s common stock the day prior to grant. Beginning in October 2019, the board decided to increase CEO base salary to $35,000 per month. On April 24, 2017 the company entered into an employment agreement with Robert Malasek, its Chief Financial Officer and Secretary. The agreement does not have a set term and may be terminated at any time by the Company or Mr. Malasek with proper notice. The shares were issued in the 1 st Industry Sponsored Research Agreement— Sapphire entered into the Industry Sponsored Research Agreement (“SRA”) effective February 7, 2020 to test and confirm the inhibitory activity of SBI-183 (exclusively licensed on January 13, 2020) and SBI-183 analogs, including those synthesized by the Company. The testing will include cell-based in vitro assays, NMR binding studies and testing to determine if SBI-183 enhances the activity of cytotoxic drugs in vitro. Animal studies will also be conducted under the SRA. Specifically, SBI-183 analogs will be evaluated in a mouse model of triple negative breast cancer using human tumor xenografts. The work will be performed over a period of one year with the total cost of the SRA totaling $150,468 paid prior to acquisition. For the year December 31, 2021, the Company recorded research and development expenses of $284,869 On August 5, 2020 Sapphire was awarded a $395,880 phase I Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The grant will support continued development of novel small molecules that inhibit the enzymatic activity of Quiescin Sulfhydryl Oxidase I (QSOX1) based on a lead compound. QSOX1 is a tumor-derived enzyme that is important for cancer growth, invasion and metastasis. Sapphire is conducting this research with technology it has exclusively licensed from Skysong Innovations, LLC, the intellectual property management company for Arizona State University. Sapphire will subcontract tumor biology work for evaluating analog inhibitors for QSOX1 to Dr. Doug Lake’s laboratory at Arizona State University and Mayo Clinic Arizona. Grant income received for the years ended 2021 and 2020 was $279,981 and $115,899; respectively. On August 25, 2020 we signed an exclusive licensing, manufacturing and distribution agreement with Empowered Diagnostics LLC to execute the high-volume production of our rapid point-of-care diagnostic test. AXIM and Empowered have completed the technology transfer and Empowered Diagnostics has built out their production facility to be able to manufacture millions of our neutralizing antibody tests for COVID-19 per month. In exchange for this license Empowered will pay Axim a royalty on net sales on all licensed products sold by Empowered covered by this license which global with the exception of Mexico. This agreement was cancelled in February, 2022 Operating Lease Lease Agreement—On March 3, 2020, Sapphire entered into a 3-year lease agreement (“Lease”) to relocate to a larger space within the same business park. The new space totals 1,908 square feet with monthly base rent in the 1st year $4,713, 2nd year $4,854 and 3rd year $5,000 at implicit interest rate of 6%. Upon commencement of the Lease on April 25, 2020, the previous lease will expire. Operating Leases - Right of Use Assets and Purchase Commitments Right of Use Assets We have operating leases for office space that expire through 2023. Below is a summary of our right of use assets and liabilities as of December 31, 2021. Right-of-use assets $ 76,871 Lease liability obligations, current $ 56,871 Lease liability obligations, noncurrent 20,000 Total lease liability obligations $ 76,871 Weighted-average remaining lease term 1.58 years Weighted-average discount rate 6 % The following table summarizes the lease expense for the years ended December 31, 2021 and 2020: December 31, December 31, 2021 2020 Operating lease expense $ 57,684 * $ 32,991 Short-term lease expense 15,711 20,831 Total lease expense $ 73,395 $ 53,822 *We recorded $54,667 of operating lease expense this includes $11,545 of maintenance charges. Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of December 31, 2021, are as follows: 2022 $ 59,416 2023 20,000 Total minimum payments 79,416 Less: amount representing interest (2,545 ) Total $ 76,871 Litigation As of December 31, 2021, and this report issuing date, the Company is not a party to any pending material legal proceeding. To the knowledge of management, no federal, state or local governmental agency is presently contemplating any proceeding against the Company. To the knowledge of management, no director, executive officer or affiliate of the Company, any owner of record or beneficially of more than five percent of the Company’s Common Stock is a party adverse to the Company or has a material interest adverse to the Company in any proceeding.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
INCOME TAXES
INCOME TAXES	NOTE 18: INCOME TAXES The Company utilizes ASC 740 “Income Taxes,” which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The U.S. tax reform bill that Congress voted to approve December 20, 2017, also known as the “Tax Cuts and Jobs Act,” made sweeping modification to the Internal Revenue Code, including a much lower corporate tax rate, changes to credits and deductions, and a move to a territorial system for corporations that have overseas earnings. The Act replaced the prior law graduated corporate tax rate, which taxed income over $10 million at 35%, with a flat rate of 21%. The Coronavirus Aid, Relief and Economy Security (CARES) Act (“the CARES Act, H.R. 748”) was signed into law on 27 March 2020. The CARES Act temporarily eliminates the 80% taxable income limitation (as enacted under the Tax Cuts and Jobs Act of 2017) for NOL deductions for 2018-2020 tax years and reinstated NOL carrybacks for the 2018-2020 tax years. Moreover, the CARES Act also temporarily increases the business interest deduction limitations from 30% to 50% of adjusted taxable income for the 2019 and 2020 taxable year. Lastly, the Tax Act technical correction classifies qualified improvement property as 15-year recovery period, allowing the bonus depreciation deduction to be claimed for such property retroactively as if it was included in the Tax Act at the time of enactment. The Company does not anticipate a material impact on its financial statements as of December 31, 2021 due to the recent enactment. For the period ended December 31, 2021, the Company had available, for Federal income tax purposes, net operating losses of $9,024,000 which expire at various dates through December 31, 2030 and $26,706,957 which have no expiration date. The net operating loss carryovers may be subject to limitations under Internal Revenue Code section 382, due to significant changes in the Company’s ownership. If a change of ownership has occurred the net operating loss carryovers would be limited or might be eliminated. The provision for income taxes differ from the amount of income tax determined by applying the applicable U.S. statutory rate to losses before income tax expense for the period ended December 31, 2021 and 2020 as follows: 2021 2020 Expected tax at statutory rates 21.00 % 21.0 % State Income Tax, Net of Federal benefit 6.98 % 11.9 % Current Year Change in Valuation Allowance -28.62 % 32.9 % Prior Year NOL True-Ups 0.64 % 0 % Effective Tax Rate 0.00 % 0.00 % 2021 2020 Statutory federal income tax rate 21.0 % 21.0 % Statutory state and local income tax rate , net of federal benefit 11.9 % 11.9 % Change in valuation allowance (32.9 %) (32.9 %) Effective tax rate 0.00 % 0.00 % Deferred income taxes result from temporary differences in the recognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset result principally from the following: 2021 2020 Stock Compensation 967,019 646,963 Amortization 608,354 24,082 Interest 66,376 66,376 Net Operating Loss Carry Forward 9,722,122 6,038,109 Valuation Allowance (11,363,871 ) (6,775,530 ) Total gross deferred tax assets (0.00 ) (0.00 ) 2021 2020 Deferred tax assets Federal*: Net operating loss carry forward $ 6,327,783 $ 6,022,948 Less: valuation allowance (6,327,783 ) (6,022,948 ) Net deferred tax asset $ - $ - The Company is subject to taxation in the U.S. and various states and foreign jurisdictions. U.S. federal income tax returns for 2018 and after remain open to examination. We and our subsidiaries are also subject to income tax in multiple states and foreign jurisdictions. Generally, foreign income tax returns after 2018 remain open to examination. No income tax returns are currently under examination. As of December 31, 2021 and 2020, the Company does not have any unrecognized tax benefits, and continues to monitor its current and prior tax positions for any changes. The Company recognizes penalties and interest related to unrecognized tax benefits as income tax expense. For the years ended December 31, 2021 and 2020, there were no penalties or interest recorded in income tax expense.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2021
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 19: SUBSEQUENT EVENTS Common Stock Issuances During January 2022, the Company issued 519,247 shares for cash of gross proceeds of $75,000 pursuant to various stock purchase agreements. The cash was received in the fourth quarter2021 and first quarter 2022. The Company also issued warrants to purchase an aggregate of 519,247 shares of common stock at an average exercise price of $0.315 per share. The warrants are exercisable within a 3-year period from issuance. In January 2022, the Company issued 7,000,000 shares of its common stock pursuant to its asset acquisition of Advanced Tear Diagnostics. In January 2022, the Company issued 302,115 of its shares of common stock, valued at $100,000, in exchange for services which have been recorded as a prepaid expense. On January 11, 2022, the company issued 282,759 shares of common stock upon the exercise of 500,000 options at an exercise price of $0.126 a share. This exercise was performed on a cashless basis. In March 2022, the Company issued 624,290 of its shares of common stock pursuant to a stock purchase agreement for cash gross proceeds of $55,000. In March 2022, the Company issued 173,390 shares of its common stock, valued at $32,944, in settlement of interest due to prepayment of a note. In March 2022, the company issued 500,000 of its shares of common stock in exchange for services related to the arrangement of meetings and conferences. The Company also issued 4,500,000 shares of its common stock January thru March of 2022 for cash of $530,228 pursuant to an equity purchase agreement, dated on May 14, 2021, which shares were registered pursuant to that S-1 Registration Statement filed by the Company with the SEC on May 14, 2021, and declared effective by the SEC on June 22, 2021. Changes to the Company’s Board of Directors On January 4, 2022, Mauricio Gatto Bellora tendered his resignation as a member of the Company’s Board of Directors, and the Company on that date accepted his resignation. Mr. Bellora’s decision to resign was not the result of any disagreement with the Company. On January 6, 2022, the record holder of 500,000 shares of the Company’s Series C Preferred Stock, representing 100% of the 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are entitled to cast a vote for election of up to four Series C Directors, whether by shareholder meeting (annual or special) or by written consent, acting pursuant to Section 78.320 of the Nevada Revised Statutes and Article III, Section 3 of the Company’s Amended and Restated Bylaws, consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto Bellora. Mr. Blake N. Schroeder, 42, began his career with a commercial litigation law firm in Salt Lake City, Utah. Beginning in 2008, Schroeder focused on the sale and marketing of natural products and opening international marketplaces to those products. From 2008 to 2014 Mr. Schroeder served in various capacities at MonaVie, LLC developing international business plans and growing international businesses. From August 2014 to February 2016, Mr. Schroeder served as the Chief Operating Officer of Forevergreen International, where he was responsible for global operation and sales of the multinational organization, including oversight of a global supply chain. From 2021 to the present, Mr. Schroeder has served as the Chief Executive Officer and Chairman of the Board of Medical Marijuana, Inc. From 2016 to the present, Mr. Schroeder serves as the chief executive officer of Kannaway USA, LLC, a wholly owned subsidiary of Medical Marijuana, Inc. Medical Marijuana, Inc. is one of the Company’s largest shareholders holding approximately 16.4% of the Company’s common stock, as of January 10, 2022. Mr. Schroeder holds a B.S. in Finance from Utah State University and a law degree from Syracuse University College of Law. Debt Obligations Effective February 10, 2022, The Company issued the following debt obligations in exchange for cash. A portion of the funds received by the Company were used to pay off the GS Capital Partners, LLC note, as discussed below. Short Term Promissory Notes Effective February 10, 2022, the Company issued two short term notes, each having a face amount of $250,000, in exchange for a total of $500,000 in cash (the “Short Term Promissory Notes”). The Short Term Promissory Notes bear interest at the rate of 1.5% per annum and were due and payable on or before March 10, 2022, unless demand for payment is made prior to such date. One of the two notes was paid in full on February 14, 2022. Convertible Notes Effective February 10, 2022, the Company issued seven convertible notes to a series of investors having an aggregate face value of $1,325,000 in exchange for $1,325,000 in cash (the “Convertible Notes”). One of the Convertible Notes, face value $25,000, was purchased by Blake N. Schroeder who is a director of the Company. Each of the Convertible Notes is (i) unsecured; (ii) bears interest at a rate of 3% per annum; (iii) matures on February 10, 2032; and (iv) is convertible, in whole or in part, at any time by the holder, into restricted shares of the Company’s common stock at a conversion price equal to the lesser of $0.08125 or 70% of the average of the two lowest closing prices of the Company’s common stock in the ten trading days preceding any particular conversion, provided, the holder is prohibited from converting the convertible note, or portion thereof, if such conversion would result in beneficial ownership by the holder and its affiliates of more than 4.999% of Company’s issued and outstanding common stock as of the date of the conversion. Note Repayments On February 10, 2022, the Company paid in full the remaining balance due on that certain convertible note issued to GS Capital Partners, LLC, face value $1,110,000 (as amended, the “GS Note”). In connection with the repayment, the Company was required to pay accrued interest in the amount of $21,875, by issuing 173,390 restricted shares of the Company’s common stock pursuant to the formula set forth in the GS Note. Changes in the Business On March 7, 2022, the Company announced that is has shifted its focus for its rapid COVID-19 Neutralizing Antibody (“Nab”)(NAb) Test to become For Research Use Only (“RUO”). The test will provide researchers an important tool for COVID-19 research and is not intended for use in diagnostic procedures. The Company has also entered a separation agreement with Empowered Diagnostics, LLC following the FDA recall of Empowered’s products, including the NabNAb test.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
Use of estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. Significant estimates are assumptions about collection of accounts receivable, useful life of intangible assets and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate and expected dividend rate.
Operating lease	We lease property under various operating leases which are disclosed on our Balance sheet in accordance with ASC 842
Risks and uncertainties	The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows; ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations. There have been no material changes in the accounting policies from those disclosed in the financial statements and the related notes included in the Form 10-K.
Cash equivalents	The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. As of December 31, 2021, the Company had no cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company had no uninsured balances at December 31, 2021. The Company has never experienced any losses related to these balances.
Accounts Receivable	It is the Company’s policy to review accounts receivable at least on a monthly basis for conductibility and follow up with customers accordingly. Covid19 has slowed collection as our customers are in a mandated pause. We do not have geographic concentration of customers.
Concentrations	At December 31, 2021, there was no accounts receivable. For the year ended December 31, 2021, one customer accounted for 21% of total revenue. For the year ended December 31, 2020, two customers accounted for 95% of total revenue. Revenue was all generated from discontinued operations for the twelve months ending December 31, 2021 and 2020.
Property and equipment	Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. The Company’s property and equipment relating to continuing operations consisted of the following at December 31, 2021 and 2020, respectively, and none related to discontinued operations. December 31, 2021 December 31, 2020 Equipment of continuing operations $ 175,283 $ 134,788 Less: accumulated depreciation $ 58,473 $ 30,694 $ 116,810 $ 104,094
Intangible Assets	Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. We conduct an impairment analysis for goodwill annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. We first may assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test included in U.S. GAAP. To the extent our assessment identifies adverse conditions, or if we elect to bypass the qualitative assessment, goodwill is tested using a quantitative impairment test. Impairment of Indefinite-Lived Intangible Assets For indefinite-lived intangible assets such as in-process research and development (IPRD), we conduct an impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist. We first perform a qualitative assessment to determine if it is more likely than not that the carrying amount of each of the in-process research and development assets exceeds its fair value. The qualitative assessment requires the consideration of factors such as recent market transactions, macroeconomic conditions, and changes in projected future cash flows. If we determine it is more likely than not that the fair value is less than its carrying amount of the in-process research and development assets, a quantitative assessment is performed. The quantitative assessment compares the fair value of the in-process research and development assets to its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized for the excess. We elected to perform a quantitative assessment of indefinite-lived intangible assets and determined that the fair value of the goodwill and IPRD related to the Sapphire acquisition was less than its carrying amount and that in-process research and development were fully impaired The Company’s intangible assets relating to continuing operations and discontinued operations consisted of the following at December 31, 2021 and 2020, respectively December 31, December 31, 2021 2020 Goodwill $ - $ 2,458,233 Intellectual Property (IPRD) - 7,800,000 Patents 250,000 - Licenses 4,270,000 - 4,520,000 10,258,233 Less: accumulated amortization 136,127 - $ 4,383,873 $ 10,258,233 Estimated aggregate amortization expense for each of the five succeeding years ending December 31 is as follows: 2022 2023 2024 2025 2026 and thereafter Amortization expense $ 375,500 $ 375,500 $ 375,500 $ 375,500 $ 2,881,873 Amortization expense recorded for the years ended December 31, 2021 and 2020 was $2,087,908 and $0; respectively. The Company recognized and impairment charge of $2,458,233 and $5,848,219 related to Goodwill and IPRD; respectively in 2021. Goodwill and Intangible assets were impaired resulting in a net impairment loss of $5,966,452, resulting from an FDA decision not to approve our COVID test.
Revenue Recognition	The Company follows the guidance contained in Topic 606 (FASB ASC 606). The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods of services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. All revenue was from operations that were divested. Revenues are recognized when title for goods is transferred; non-refundable fees and proceeds from irrevocable agreements recognized when inflows or other enhancements of assets of the Company are received. Revenues from continuing operations recognized for twelve months ended December 31, 2021 and 2020 amounted to $60,460 and $-0-, respectively. Revenues from discontinued operations recognized for twelve months ended December 31, 2021 and 2020 amounted to $0 and $7,990, respectively.
Collaboration Revenue	Collaboration Revenue Revenue recognition for collaboration agreements will require significant judgment. The Company’s assessments and estimates are based on contractual terms, historical experience and general industry practice. Revisions in these values or estimations have the effect of increasing or decreasing collaboration revenue in the period of revision. On August 21, 2020, the Company entered into a Distribution, License and Supply Agreement (“License Agreement”) with Empowered Diagnostics, LLC (“Empowered Diagnostics”). The License Agreement provides Empowered Diagnostics with a right to commercialize The company’s products worldwide with the exception of Mexico. Under the License Agreement, the company is responsible for applying for and obtaining necessary regulatory approvals in the US and EU, as well as marketing, sales and distribution of the products. Empowered Diagnostics will pay a transfer price for all licensed products, and upon achievement of certain regulatory and sales milestones, the Company may receive payments from Empowered Diagnostics equal to 8% of the monthly gross revenue. Agreement continues until terminated by mutual consent or uncorrected breach. This agreement with Empowered Diagnostics was terminated in February, 2022 The Company did not recognize any revenue from this agreement, Grant Income In 2021 the Company has received government grants to drive its research and development efforts. Through these government grants, the government has provided funding for the Company to perform research and development activities which will assist in developing its products. The Company believes the government entities funding these grants are interested in the Company advancing its underlying technologies through research activities and not providing incentives for hiring employees or building facilities that would suggest that the grant monies are not for specific research activities. In determining how to classify the monies received under government grants, the Company acknowledges that there is no specific guidance under US GAAP and that the FASB and AICPA have often drawn upon the guidance in IAS 20 for classification. In considering the alternatives provided by IAS 20 for the presentation of these grants in the Company’s financial statements, the Company believes that recognizing the government grant proceeds as a component of other revenue is a better reflection of the economics of the arrangements as the Company earns the funding through the performance of research and development which is not one of the Company’s primary business activities or central to its operations. The Company believes that presenting research and development funding from government grants, as other revenue provides consistency in our financial reporting. The Company also believes that this presentation clearly presents to users of its financial statements in one line the Company’s sources of funding from these grants. The Company notes that there are no contingencies associated with the receipt of or ability to retain the funds under the grant, other than undertaking and performing the related research and development activities. The Company recognizes funds received from contractual research and development services and from government grants as other revenue. These contracts and grants are not considered an ongoing major and central operation of the Company’s business. Our Income from Grants from Government for the years ended December 31, 2021 and 2020, was $279,981 and $115,899 respectively.
Cost of Sales	Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to the customers including buying and transportation costs. Cost of sales all related to discontinued operations.
Shipping Costs	Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in general and administrative expenses. Shipping costs all related to discontinued operations.
Fair Value Measurements	The Company applies the guidance that is codified under ASC 820-10 related to assets and liabilities recognized or disclosed in the financial statements at fair value on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The Company’s financial instruments are cash and cash equivalents, accounts receivable, accounts payable, notes payable, and long-term debt. The recorded values of cash and cash equivalents and accounts payable approximate their fair values based on their short-term nature. The recorded values of notes payable and long-term debt approximate their fair values, as interest approximates market rates. ASC 820-10 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820-10 requires valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows: Fair Value Hierarchy Inputs to Fair Value Methodology Level 1 Quoted prices in active markets for identical assets or liabilities Level 2 Quoted prices for similar assets or liabilities; quoted markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the financial instrument; inputs other than quoted prices that are observable for the asset or liability; or inputs that are derived principally from, or corroborated by, observable market information Level 3 Pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption is unobservable or when the estimation of fair value requires significant management judgment For the twelve months ended December 31, 2021 and 2020 The Company recorded unrealized gain (loss) on marketable securities of $0 and $(104,705), respectively, and realized gain (loss) on marketable securities of $0 and $(109,040), respectively. The Company had no marketable securities as of December 31, 2021 and 2020. The Company did not have any Level 2 or Level 3 assets or liabilities as of December 31, 2021 and 2020. The fair value of the Company’s convertible promissory notes is estimated based on the current rates offered to the Company for debt of similar terms and maturities. Under this method, the Company’s fair value of convertible debt was not significantly different from the carrying value at December 31, 2021. The Company’s acquired goodwill with a carrying amount of $2,458,233 were written down to zero, resulting in an impairment charge of $2,458,233, which was included in earnings for the period. In-process Research and Development with a carrying amount of $5,848,219 was written down to its implied fair value of zero, resulting in an impairment charge of $5,848,219, which was included in earnings for the period.
Convertible Instruments	The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities.” Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.
Income Taxes	The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. No amounts were accrued for the payment of interest and penalties as of December 31, 2021 and 2020. The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2021 and 2020. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “Cares Act”) was enacted. The CARES Act included loans and grants to certain businesses, and temporary amendments to the Internal Revenue Code which changed net loss carryforward and back provisions and the business interest expenses limitation. Under the CARES Act provisions, the most relevant income tax considerations to Oncocyte relate to the amounts received under the Paycheck Protection Program loan program and the possible forgiveness of those loans by the SBA. On December 21, 2020, the U.S. president has signed into law the “Consolidated Appropriations Act, 2021” which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans can deduct regular business expenses that are paid for with the loan proceeds for federal tax purposes. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant.
Concentrations of Credit Risk	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company had $0 and $240,769 allowance for doubtful accounts at December 31, 2021 and 2020, respectively and had $0 accounts receivable at December 31, 2021 and $240,769 at December 31, 2020, all was related to discontinued operations.
Net Loss per Common Share	Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. There were common share equivalents 30,119,877 at December 31, 2021 and 32,556,727 at December 31, 2020. For the year ended December 31, 2021 and 2020 these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share.
Stock Based Compensation	All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued. The Company accounts for stock options issued to non-employees based on the estimated fair value of the awards using the Black-Scholes option pricing model in accordance with ASC 505-50, Equity-Based Payment to Non-employees
Research and Development	The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the twelve months ended December 31, 2021 and 2020 The Company incurred research and development expenses of $284,869 and $426,708 from continuing operations, respectively. For the twelve months ended December 31, 2021 and 2020 the Company incurred research and development expenses of $0 and $377,416 from discontinued operations, respectively. The Company has entered into various agreements with CROs. The Company’s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.
Recently Issued Accounting Standards	Accounting Standards Implemented Since December 31, 2020 ASC Update 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in this Update do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic. That is, accounting for those instruments continues to be subject to the requirements in other Topics. The amendments in this Update do not affect a holder’s accounting for freestanding call options. ASC Update No. 2020-10 In October 2020, the FASB issued ASC Update No. 2020-10, Codification Improvements. Update No. 2020-10 amends a wide variety of Topics in the Codification in order to improve the consistency of the Codification and the application thereof, while leaving Generally Accepted Accounting Principles unchanged. ASC Update No. 2020-06 In August 2020, the FASB issued ASC Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in Update No. 2020-06 simplify the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity’s own equity Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

ACQUISITION OF SAPPHIRE BIOTE_2

ACQUISITION OF SAPPHIRE BIOTECH, INC. (Tables)	12 Months Ended
	Dec. 31, 2021
ACQUISITION OF SAPPHIRE BIOTECH, INC.
Schedule of consideration paid	Consideration: Cash and cash equivalents $ 79,814 Property and equipment, net 20,533 In process R&D 7,800,000 Goodwill 2,458,233 Security deposit 12,785 Total asset acquired $ 10,371,365 Accrued expenses and other current liabilities $ 5,767 Deferred taxes liability 2,340,000 Notes Payable including convertible and discount on conversion 519,598 Total liabilities assumed $ 2,865,365 Net assets acquired $ 7,506,000 For twelve months ended December 31, 2021 December 31, 2020 Revenues $ - $ - Net loss from continuing operations $ (16,024,309 ) $ (6,290,906 ) Net income (loss) from discontinued operations $ (7,996 ) $ (119,293 ) Net loss per share—Basic and Diluted $ (0.12 ) $ (0.06 )

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
Schedule of property and equipment relating to continuing operations	December 31, 2021 December 31, 2020 Equipment of continuing operations $ 175,283 $ 134,788 Less: accumulated depreciation $ 58,473 $ 30,694 $ 116,810 $ 104,094
Schedule of intangible assets	December 31, December 31, 2021 2020 Goodwill $ - $ 2,458,233 Intellectual Property (IPRD) - 7,800,000 Patents 250,000 - Licenses 4,270,000 - 4,520,000 10,258,233 Less: accumulated amortization 136,127 - $ 4,383,873 $ 10,258,233
Estimated aggregate amortization expense	2022 2023 2024 2025 2026 and thereafter Amortization expense $ 375,500 $ 375,500 $ 375,500 $ 375,500 $ 2,881,873

PREPAID EXPENSES (Tables)

PREPAID EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2021
PREPAID EXPENSES
Schedule of Prepaid Expenses	December 31, December 31, 2021 2020 Prepaid insurance $ 59,116 $ 45,983 Prepaid services 104,445 209,940 $ 163,561 $ 255,923

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2021
CONVERTIBLE NOTES PAYABLE
Schedule of Convertible Notes Payable, Shareholder	December 31, December 31, 2021 2020 Convertible note payable, due on November 1, 2026, interest at 3.5% p.a. $ 4,000,000 $ 4,000,000 Accrued interest 299,037 158,648 Convertible note payable, net $ 4,299,037 $ 4,158,648 December 31, December 31, 2021 2020 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. $ 484,478 $ 484,478 Convertible Note Payable, due on October 1, 2022, interest at 6% p.a. 1,110,000 - Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. 500,000 1,000,000 Convertible note payable, due on December 31, 2034, interest at 3% p.a. 190,000 190,000 Convertible note payable, due on July 21, 2032, interest at 3.5% p.a. - 609,835 Accrued interest (The accrued interest and principal are both included in the captions titled “convertible note payable” in the balance sheet) 209,685 236,148 Total 2,494,163 2,520,461 Less: unamortized debt discount/finance premium costs (605,639 ) (843,673 ) Convertible note payable, net $ 1,888,524 $ 1,676,788

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2021
STOCK OPTIONS AND WARRANTS
Schedule of Stock option activity	Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2019 2,000,000 $ 0.75 Granted 8,300,000 0.27 Exercised - - Expired or canceled - - Outstanding at December 31, 2020 10,300,000 0.36 Granted 2,960,715 0.60 Exercised (300,000 ) 0.35 Expired or canceled (2,000,000 ) 0.75 Outstanding at December 31, 2021 10,960,715 $ 0.37
Schedule of assumptions to determine value of share-based compensation for options	December 31, December 31, 2021 2020 Expected life (years) 10 10 Risk-free interest rate (%) 1.74 0.61 Expected volatility (%) 190 230 Dividend yield (%) - - Weighted average fair value of shares at grant date $ 1.74 $ 0.61
Schedule of options under Stock Option Plan	Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.36 10,960,715 8.5 $ 0.37 8,094,046 $ 0.37 As of December 31, 2020 Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.36 10,300,000 9.8 $ 0.36 7,466,662 $ 0.36
Schedule of summarizes warrant activity	Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2020 - $ - Granted 2,850,000 0.71 Forfeited/Cancelled - - Exercised - - Outstanding at December 31, 2021 2,850,000 $ 0.71

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Dec. 31, 2021
DISCONTINUED OPERATIONS
Schedule of Discontinued Operations - Summary of assets and liabilities sold	Other current assets $ 5,000 Total current assets $ 510,017 Intangible assets, net of amortization $ 47,375 Total asset $ 562,392 Notes payable $ 880,000 Accounts payable and accrued expenses $ 210,640 Due to Canchew $ 1,526,603 Stock retired $ 1,857 Total liabilities and equity $ 2,619,100 The gain on sale of assets was reported during the period was determined as follows: Loss on sale of assets $ (562,392 ) Gain on sale of liabilities $ 2,619,100 Net gain from sale of assets and liabilities $ 2,056,708
Summary of Results of Discontinued Operations	December 31, 2021 December 31, 2020 Net sales $ - $ 5,097 Total expenses $ (7,996 ) $ (2,016,742 ) Gain from sale of asset and liability $ - $ 2,056,708 Other (loss) income $ - $ (164,356 ) (Loss) income from discontinued operations $ (7,996 ) $ (119,293 ) December 31, 2021 December 31, 2020 Net (loss) income from discontinued operations $ (7,996 ) $ 119,293 ) Adjustment of non-cash activities - 726,748 Decrease in accounts receivable - Increase in inventory - Increase in accounts payable and accrued expenses - (1,823,057 ) Net cash provided by (used in) operating activities $ (7,996 ) $ (1,215,602 ) Net cash provided by (used in) investing activities $ - $ 27,490 Net cash provided by (used in) financing activities $ - $ (65,000 )

COMMITMENT AND CONTINGENCIES (T

COMMITMENT AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2021
COMMITMENT AND CONTINGENCIES
Summary of Right of Use Assets and Liabilities	Right-of-use assets $ 76,871 Lease liability obligations, current $ 56,871 Lease liability obligations, noncurrent 20,000 Total lease liability obligations $ 76,871 Weighted-average remaining lease term 1.58 years Weighted-average discount rate 6 %
Summary of Lease Expenses	December 31, December 31, 2021 2020 Operating lease expense $ 57,684 * $ 32,991 Short-term lease expense 15,711 20,831 Total lease expense $ 73,395 $ 53,822
Schedule of Future Minimum Rental Payments for Operating Leases	2022 $ 59,416 2023 20,000 Total minimum payments 79,416 Less: amount representing interest (2,545 ) Total $ 76,871

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
INCOME TAXES
Schedule of Deferred income taxes	2021 2020 Stock Compensation 967,019 646,963 Amortization 608,354 24,082 Interest 66,376 66,376 Net Operating Loss Carry Forward 9,722,122 6,038,109 Valuation Allowance (11,363,871 ) (6,775,530 ) Total gross deferred tax assets (0.00 ) (0.00 ) 2021 2020 Deferred tax assets Federal*: Net operating loss carry forward $ 6,327,783 $ 6,022,948 Less: valuation allowance (6,327,783 ) (6,022,948 ) Net deferred tax asset $ - $ -
Schedule of provision for income taxes	2021 2020 Expected tax at statutory rates 21.00 % 21.0 % State Income Tax, Net of Federal benefit 6.98 % 11.9 % Current Year Change in Valuation Allowance -28.62 % 32.9 % Prior Year NOL True-Ups 0.64 % 0 % Effective Tax Rate 0.00 % 0.00 % 2021 2020 Statutory federal income tax rate 21.0 % 21.0 % Statutory state and local income tax rate , net of federal benefit 11.9 % 11.9 % Change in valuation allowance (32.9 %) (32.9 %) Effective tax rate 0.00 % 0.00 %

ORGANIZATION (Details Narrative

ORGANIZATION (Details Narrative) - USD ($)	May 06, 2020	May 11, 2015	Dec. 31, 2021	Mar. 06, 2020
Acquisition ownership percentage		100.00%		100.00%
Acquisition of common stock shares		5,826,706	10,000
Consideration for payment		$ 65,000
Total amount paid inconsideration	$ 2,610,000
Series B Preferred Stock [Member]
Acquisition ownership percentage		100.00%
Acquisition of common stock shares		18,570,356

ACQUISITION OF SAPPHIRE BIOTE_3

ACQUISITION OF SAPPHIRE BIOTECH INC (Details) - Sapphire [Member]	Dec. 31, 2021USD ($)
Cash and cash equivalents	$ 79,814
Property and equipment, net	20,533
In process R&D	7,800,000
Goodwill	2,458,233
Security deposit	12,785
Total asset acquired	10,371,365
Accrued expenses and other current liabilities	5,767
Deferred taxes liability	2,340,000
Notes Payable including convertible and discount on conversion	519,598
Total liabilities assumed	2,865,365
Net assets acquired	$ 7,506,000

ACQUISITION OF SAPPHIRE BIOTE_4

ACQUISITION OF SAPPHIRE BIOTECH INC (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues	$ 60,460	$ 0
Net loss from continuing operations	(16,024,309)	(6,290,587)
Net income (loss) from discontinued operations	(7,996)	(119,293)
Sapphire [Member]
Revenues	0	0
Net loss from continuing operations	(16,024,309)	(6,290,906)
Net income (loss) from discontinued operations	$ (7,996)	$ (119,293)
Net loss per share-Basic and Diluted	$ (0.12)	$ (0.06)

ACQUISITION OF SAPPHIRE BIOTE_5

ACQUISITION OF SAPPHIRE BIOTECH INC (Details Narrative) - USD ($)	May 11, 2015	Sep. 30, 2020	Mar. 31, 2020	Mar. 17, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 06, 2020
Common stock shares issued					138,099,981	125,327,579
Common stock fair value					$ 13,811	$ 12,533
Liabilities					7,661,635	9,748,574
Assets					5,323,435	11,314,395
IPR&D					5,848,219
Total acquisition cost					2,609,100
Goodwill					0	2,458,233
Deferred tax liability					$ 0	$ 2,340,000
Acquisition ownership percentage	100.00%						100.00%
Acquisition of common stock shares	5,826,706				10,000
Sapphire [Member]
Number of shares exchanged				54,000,000
Purchase Price					$ 7,918,233
Common stock shares issued			54,000,000
Common stock fair value		$ 7,506,000	$ 7,506,000
Liabilities		412,233	412,233		525,365
Assets					113,132
IPR&D					7,800,000
Total acquisition cost			7,918,233
Common stock fair value based on closing pice		7,506,000
Acquisition-related costs			$ 6,000
Goodwill		2,458,233			118,233
Deferred tax liability					2,340,000
Acquisition ownership percentage				100.00%
Acquisition of common stock shares				100,000,000
Aggregate purchase price		$ 7,918,233
Impairment loss					$ 5,966,452
Sapphire [Member] | Convertible Notes Payable 1 [Member]
Convertible notes principal amounts				$ 310,000
Sapphire [Member] | Convertible Notes Payable 2 [Member]
Convertible notes principal amounts				$ 190,000

ACQUISITION OF INTELLECTUAL P_2

ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC, LLC. (Details Narrative) - USD ($)	May 11, 2015	Aug. 26, 2021	Jul. 29, 2021	Dec. 31, 2021
Purchase Price acquisition				$ 2,609,100
Acquisition of common stock shares	5,826,706			10,000
Tear Diagnostics LLC [Member]
Purchase price			$ (210,000)
Purchase Price acquisition				$ 4,520,000
Monthly payments			$ 30,000
Licenses fee		$ 4,270,000
Acquisition of common stock shares		7,000,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Mar. 11, 2019	Apr. 16, 2018	Dec. 31, 2021	Dec. 31, 2020
Working capital deficit			$ (1,944,381)
Accumulated deficit			(57,882,227)	$ (41,849,922)
Cash used in operating activities of continuing operations			(2,478,769)
Stock Purchase Agreement [Member]
Share issued amount reduced	$ 400,000
Additional capital raised			$ 1,610,538
Share sold during period		1,945,000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Equipment of continuing operations	$ 175,283	$ 134,788
Less: accumulated depreciation	58,473	30,694
Property, Plant and Equipment, Net	$ 116,810	$ 104,094

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Goodwill	$ 0	$ 2,458,233
Intellectual Property (IPRD)	0	7,800,000
Patents	250,000	0
Licenses	4,270,000	0
Finite-Lived Intangible Assets, Gross	4,520,000	10,258,233
Less: accumulated amortization	136,127	0
Intangible Assets, Net	$ 4,383,873	$ 10,258,233

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2)	Dec. 31, 2021USD ($)
SIGNIFICANT ACCOUNTING POLICIES
2022	$ 375,500
2023	375,500
2024	375,500
2025	375,500
2026 and thereafter	$ 2,881,873

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash and cash equivalents	$ 0
Acquisition from goodwill	2,458,233
Goodwill impairment charge	2,458,233
Amortization expense	2,087,908	$ 0
Allowance for doubtful accounts	0	240,769
Accounts receivable	0	240,769
Revenues from continuing operations	60,460	0
Revenues from discontinuing operations	0	7,990
Income from Grants from Government	$ 279,981	$ 115,899
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	30,119,877	32,556,727
Research and Development Expense from continuing operation	$ 284,869	$ 426,708
Research and Development Expense from discontinuing operation	0	377,416
Unrealized gain (loss) on marketable securities	0	104,705
Realized gain (loss) on marketable securities	0	$ (109,040)
Acquired goodwill carrying amount	2,458,233
In-process Research and Development	5,848,219
Impairment charge	$ 5,848,219
Two Customer [Member]
Concentrations percentage, revenue		95.00%
One Customer [Member]
Concentrations percentage, revenue	21.00%
Other Intangible Assets [Member]
Impairment charge	$ 5,966,452
In Process Research and Development [Member]
Impairment charge	$ 5,848,219

PREPAID EXPENSES (Details)

PREPAID EXPENSES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
PREPAID EXPENSES
Prepaid insurance	$ 59,116	$ 45,983
Prepaid services	104,445	209,940
Prepaid expenses	$ 163,561	$ 255,923

PREPAID EXPENSES (Details Narra

PREPAID EXPENSES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
PREPAID EXPENSES
Amortization of prepaid insurance	$ 376,936	$ 253,376
Amortization of prepaid expenses	$ 376,936	$ 253,376

PROMISSORY NOTE (Details Narrat

PROMISSORY NOTE (Details Narrative) - USD ($)	May 06, 2020	Aug. 08, 2014	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jul. 29, 2021
consideration transfers	$ 2,610,000
Interest transefer	100.00%
Interest Expense				$ 247,792	$ 234,754
Accrued Liabilities, Current				1,701	675
Accrued interest				16,919	0
Promissory Note [Member]
Interest Expense				0	0
Debt Exchange Agreement [Member]
Accrued Liabilities, Current				363,178	$ 343,725
Tear Diagnostics LLC [Member]
Note payable						$ 210,000
Note balance				90,000
Accrued interest				$ 1,515
Can Chew Biotechnologies [Member] | Promissory Bote Agreement [Member]
Working Capital		$ 1,000,000
Debt Instrument, Interest Rate During Period		7.00%
Can Chew Biotechnologies [Member] | Debt Exchange Agreement [Member]
Debt Instrument, Interest Rate During Period			6.00%
Sapphire Biotech [Member] | Debt Exchange Agreement 7 [Member]
Interest Expense			$ 14,218
Loans Assumed			310,000
Sapphire Biotech [Member] | Debt Exchange Agreement [Member]
Debt Instrument, Face Amount			324,218
Sapphire Biotech [Member] | Debt Exchange Agreement 3 [Member]
Loans Assumed			$ 128,375

OTHER COMMITMENTS (Details Narr

OTHER COMMITMENTS (Details Narrative) - USD ($)	Jan. 02, 2019	Jul. 31, 2021	Apr. 30, 2020	Mar. 31, 2020	Sep. 25, 2018	Mar. 20, 2018	May 31, 2014	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021	Mar. 06, 2020	Dec. 31, 2019	May 11, 2015
Monthly bonus fee	$ 15,000
Consulting fees	$ 20,000									$ 40,000	$ 225,000
Implicit interest rate										5.00%
Indebtedness amount													$ 2,610,000
Issued and outstanding shares purchase percentage													100.00%
Common stock held in treasury													18,570,356
Issued and outstanding shares													500,000
Payment for issued and outstanding shares										$ 65,000
Cash compensation					$ 20,000
Acquisition ownership percentage													100.00%		100.00%
Restrictive shares issued during period								11,260,715	10,960,715	10,960,715	10,300,000	8,300,000		2,000,000
Compensation expenses								$ 1,143,730		$ 1,947,745
S-8 Shares, shares									500,000
Gross proceeds from the sale of S-8 Shares									$ 129,274
S-8 Shares, amount									129,274
Mr Changoer [Member]
Consulting fees										20,000	$ 60,000
Restrictive shares issued during period						50,000
Compensation expenses						$ 235,000
Accrued severance payment in account payable									20,000	20,000
Severance cost										20,000
Chairman [Member]
Amount owes to chairman							$ 5,000
Working capital advance							$ 5,000
Dr. Anastassov [Member]
Accrued severance payment in account payable									40,000	$ 40,000
Severance cost		$ 20,000	$ 20,000	$ 35,000
S-8 Shares, shares										150,000
Gross cash proceeds from the sale of shares in lieu of cash severance										$ 20,000
Monthly severance obligation										20,000
Gross proceeds from the sale of S-8 Shares										20,000
S-8 Shares, amount										15,000
Van Demme [Member]
Cash compensation					20,000
Severance cost										5,000
Monthly clinical trial fee					$ 5,000
Accounts payable									$ 0	$ 0	$ 25,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	May 24, 2020	May 04, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 17, 2020
Accounts and Financing Receivable, after Allowance for Credit Loss			$ 102,567	$ 102,567
Accrued Liabilities, Current			1,701	675
Common stock to be issued	$ 900,000
Loss on Extinguishment of Debt			$ 1,587,027	$ 923,605
Dr. Sergei A. Svarovsky [Member]
Accounts Payable, Related Parties, Current					$ 15,000
Catlina Valencia [Member]
Accounts Payable, Related Parties, Current					$ 15,000
Purchase Promissory Note [Member] | Dr Anastassov [Member] | Forbearance Agreement [Member]
Accounts and Financing Receivable, after Allowance for Credit Loss		$ 102,567
Common stock to be issued		135,000
Loss on Extinguishment of Debt		32,433
Debt Instrument, Face Amount		350,000
Note payable		100,000
Due to Related Parties, Current		$ 100,000

DUE TO FIRST INSURANCE FUNDING

DUE TO FIRST INSURANCE FUNDING (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jun. 25, 2021	Jun. 25, 2020
DUE TO FIRST INSURANCE FUNDING
Insaurance renewal fee			$ 98,888	$ 93,357
Cash down payment			$ 24,273	$ 18,671
Interest rate			4.42%	4.60%
Premium paid			$ 1,797	$ 8,546
Total Outstanding amount	$ 32,873	$ 25,369

CONVERTIBLE NOTES PAYABLE Sched

CONVERTIBLE NOTES PAYABLE Schedule of Convertible Notes Payable Shareholder (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument, Maturity Date	Nov. 1, 2026
Debt Instrument, Interest Rate, Stated Percentage	3.50%
Accrued interest	$ 16,919	$ 0
Convertible notes payable due to shareholder
Debt Instrument, Face Amount	4,000,000	4,000,000
Accrued interest	299,037	158,648
Convertible note payable, net	$ 4,299,037	$ 4,158,648

CONVERTIBLE NOTES PAYABLE Sch_2

CONVERTIBLE NOTES PAYABLE Schedule of Convertible Note Payable of Related Party (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Less: unamortized debt discount/finance premium costs	$ (605,639)	$ (843,673)
Convertible Note Payable Net	1,888,524	1,676,788
Total	1,126,919	0
Convertible note payable
Accrued interest (The accrued interest and principal are both included in the captions titled "convertible note payable" in the balance sheet)	209,685	236,148
Total	2,494,163	2,520,461
Convertible Note Payable 1 [Member]
Total	484,478	484,478
Convertible Note Payable 2 [Member]
Total	1,110,000	0
Convertible Note Payable 3 [Member]
Total	500,000	1,000,000
Convertible Note Payable 5 [Member]
Total	0	609,835
Convertible Note Payable 4 [Member]
Total	$ 190,000	$ 190,000

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	Jun. 07, 2021	May 11, 2015	Nov. 24, 2021	Sep. 27, 2021	Mar. 17, 2020	Oct. 20, 2016	Sep. 16, 2016	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 21, 2020	May 01, 2020	May 02, 2019	Mar. 01, 2017	Feb. 01, 2017
Interest expenses									$ 140,389	$ 140,389
Amortization of Debt Discount (Premium)								$ 86,059	$ 238,033
Convertible note, principal balance													$ 4,000,000
Convertible note interest rate													3.50%
Conversion price per share													$ 0.25
Conversion price per share reduced from													1.50
Original maturity date									Nov. 1, 2026
Stock modification price per share													$ 0.13
Fair value prior to the amendment													$ 4,000,000
Fair value of the Note and embedded derivatives after the amendment													$ 4,000,000
Debt Instrument, Unamortized Discount									$ 605,640	843,673
Acquisition of common stock shares		5,826,706							10,000
Total									$ 1,126,919	0
Loss on extinguishment of debt									$ 1,587,027	$ 923,605
Interest rate per annum									3.50%
Common stock price per share									$ 0.0001	$ 0.0001
Accrued interest									$ 16,919	$ 0
Secured Convertible Debt [Member]
Accrued interest									299,037	158,648
Convertible Debt									4,299,037	4,158,648
Secured Convertible Debt 1 [Member]
Accrued interest									556,420	71,942
Convertible Debt									89,134	556,420
Secured Convertible Debt 2 [Member]
Accrued interest									92,215	148,944
Convertible Debt									592,915	1,148,944
Secured Convertible Debt 3 [Member]
Accrued interest									11,416	5,716
Convertible Debt									201,416	195,716
Secured Convertible Debt 5 [Member]
Accrued interest									0	9,546
Convertible Debt									201,416	195,716
Secured Convertible Debt 4 [Member]
Accrued interest									16,919	0
Convertible Debt									$ 1,126,919	0
Medical Marijuana Inc [Member] | Debt Exchange Agreement [Member]
Accrued interest														$ 60,278
Kannaway [Member]
Accounts Receivable, after Allowance for Credit Loss, Noncurrent										$ 75,074
Convertible Note Purchase Agreement
Convertible note interest rate						3.50%	3.50%
Conversion price per share	$ 0.2201					$ 0.2201	$ 0.2201					$ 0.37
Original maturity date							Oct. 1, 2029	Jul. 21, 2032			Dec. 31, 2034
Acquisition of common stock shares							5,000,000
Secured convertible note						$ 1,000,000	$ 850,000								$ 250,000	$ 250,000
Total	$ 500,000					250,000					$ 190,000	$ 609,835
Accrued interest	$ 82,707
Common stock conversion	2,647,464		1,725,439
Loss on extinguishment of debt	$ 1,535,264							$ 823,497
Interest rate per annum											3.00%	3.50%			1.00%
Common stock price per share											$ 1.90
Secured promissory notes						250,000
Promissory notes						$ 500,000
Additionally secured number of shares						10,486,303
Additionally secured number of shares, value						$ 858,828
Debt extinguishment due to change in fair values percentage												10.00%
Common stock conversion amount			$ 28,578
Loss on conversion expense			$ 51,763
Convertible note beneficial conversion feature						$ 499,318
Share Exchange Agreement
Total					$ 190,000
Common stock conversion					6,000,000
Convertible note beneficial conversion feature					$ 190,000
Purchase Agreement with GS Capital LLC
Conversion price per share				$ 0.25
Original maturity date				Sep. 29, 2022
Total				$ 1,110,000
Interest rate per annum				6.00%
Original issue discount				$ 100,000
Bridge financing fees				100,000
Legal costs				$ 30

STOCK INCENTIVE PLAN (Details N

STOCK INCENTIVE PLAN (Details Narrative) - USD ($)

Sep. 08, 2021

Aug. 02, 2021

Sep. 10, 2020

Sep. 04, 2020

May 13, 2020

Aug. 17, 2021

May 20, 2021

May 29, 2015

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2021

Dec. 31, 2020

Stock available for issuance

8,094,046

9,806,000

Share-based Payment Arrangement, Expense

$ 1,143,730

$ 1,947,745

2015 Stock Incentive Plan [Member]

Common stock issued under registration statement on Form S-8

10,000,000

Increase of issuance shares

20,000,000

Alim Seit-Nebi [Member]

Option granted purchase shares

1,000,000

Exercise price

$ 0.126

Stock option vesting description

One third of the options will vest six months from the date of grant, one third of the options will vest one year from the date of grant

Douglas Lake [Member]

Option granted purchase shares

2,000,000

Exercise price

$ 0.126

Stock option vesting description

One third of the options will vest six months from the date of grant, one third of the options will vest one year from the date of grant, and the remaining one third of the options will vest two years from the date of grant

Timothy R, Scott [Member]

Option granted purchase shares

500,000

Exercise price

$ 0.126

Stock option vesting description

one third of the options will vest six months from the date of grant, and the remaining one third of the options will vest twelve months from the date of grant.

Robert Cunningham [Member]

Option granted purchase shares

50,000

Exercise price

$ 0.126

Stock option vesting description

one third of the options will vest six months from the date of grant, and the remaining one third of the options will vest twelve months from the date of grant.

Maurico Bellora [Member]

Option granted purchase shares

500,000

Exercise price

$ 0.126

Stock option vesting description

one third of the options will vest six months from the date of grant, and the remaining one third of the options will vest twelve months from the date of grant

Noel C. Gillespie [Member]

Option granted purchase shares

500,000

Stock option vesting description

One third of the options vested immediately, one third of the options will vest one year from the date of grant, and the remaining one third of the options will vest two years from the date of grant

Purchase price of stock option

$ 0.61

Bijan Pedram [Member]

Option granted purchase shares

100,000

Stock option vesting description

25% of the Option shares will be vested upon the one anniversary of the vesting commencement day and the balance of the option shares will be vested of thirty-six (36) successive equal monthly in the first anniversary of the vesting commencement day

Purchase price of stock option

$ 0.67

Jeft Busby [Member]

Option granted purchase shares

1,000,000

Stock option vesting description

25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day

Purchase price of stock option

$ 0.60

Laura M. Periman [Member]

Option granted purchase shares

100,000

Stock option vesting description

50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day

Purchase price of stock option

$ 0.64

Kelly K. Nichols [Member]

Option granted purchase shares

100,000

Stock option vesting description

50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day

Purchase price of stock option

$ 0.62

Joseph Tauber [Member]

Option granted purchase shares

1,000,000

Stock option vesting description

25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day

Purchase price of stock option

$ 0.622

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative)	Dec. 13, 2021USD ($)	Nov. 07, 2021USD ($)shares	Oct. 12, 2021USD ($)shares	Mar. 18, 2021USD ($)shares	Dec. 07, 2020USD ($)shares	Aug. 12, 2020USD ($)shares	Aug. 06, 2020USD ($)shares	Aug. 04, 2020USD ($)shares	Jul. 14, 2020USD ($)shares	Jul. 10, 2020USD ($)shares	Jul. 09, 2020USD ($)shares	Jul. 02, 2020USD ($)shares	Jun. 24, 2020USD ($)shares	Jun. 10, 2020USD ($)shares	May 24, 2020USD ($)	May 06, 2020USD ($)shares	Mar. 17, 2020USD ($)shares	Feb. 26, 2020USD ($)shares	Jan. 23, 2020USD ($)shares	Jan. 13, 2020USD ($)shares	Feb. 20, 2019USD ($)integershares	Aug. 18, 2016USD ($)shares	Aug. 17, 2016integershares	Oct. 18, 2021USD ($)shares	Jul. 29, 2021USD ($)shares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 18, 2021shares	Jul. 24, 2020USD ($)shares	Jul. 22, 2020USD ($)shares	Jun. 30, 2020USD ($)shares	Apr. 21, 2020shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Jan. 06, 2022shares
Preferred stock, shares authorized | shares																																5,000,000	5,000,000	5,000,000
Preferred stock, par value per share | $ / shares																																$ 0.0001	$ 0.0001	$ 0.0001
Undesignated preferred stock, shares authorized | shares																																4,000,000	4,000,000
Undesignated preferred stock, shares issued | shares																																0	0	0
Undesignated preferred stock, shares outstanding | shares																																0	0	0
Common stock, shares authorized | shares																																300,000,000	300,000,000	300,000,000
Common stock shares issued | shares																																138,099,981	138,099,981	125,327,579
Common stock, shares outstanding | shares																																138,099,981	138,099,981	125,327,579
Common stock, par value per share | $ / shares																																$ 0.0001	$ 0.0001	$ 0.0001
Stock issued upon stock options exercised | shares																																	196,438
Stock issued during period, shares, stock options exercised | shares																																	300,000
Common stock to be issued															$ 900,000
Stock Option, Exercise Price, Decrease | $ / shares																										$ 0.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term																										3 months
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares																18,570,356
Stock Issued During Period, Value, Restricted Stock Award, Forfeitures																$ 2,562,709
Stock Issued For Prepaid Marketing Expenses, shares | shares																												359,524
Stock Issued For Prepaid Marketing Expenses, value																												$ 302,000
Stock value for services	$ 100,000																																	$ 666,190
Share issued for settelment of debt | shares		1,725,439
Share issued settelment of debt amoint		$ 638,412
Accrued interest		$ 28,578
Share issued during period | shares																																500,000
Share issued during perid value																																$ 129,274
Proceeds from issuance of equity																																129,274
Finder's fees																																	$ 20,000
Stock issued, value, capital raise																																	16,000
Value of shares, rights to put or sell, maximum																																	$ 10,000,000
Common stock, shares adjusted | shares				108,965
Common stock, value adjusted				$ 66,974
Options exercised during period, exercise price | $ / shares																																	$ 0.35	$ 0
Accrued interest																																16,919	$ 16,919	$ 0
Additional paid in capital																																$ 51,000,166	51,000,166	$ 43,201,186
Conversion Of Convertible Note [Member]
Loss on extinguishment of debt																																	$ 1,535,264
July and September 2021 [Member]
Stock issued during period, shares, restricted shares | shares																																	1,415,554
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																																	$ 1,111,900
September 2021 [Member]
Stock issued during period, shares, restricted shares | shares																																	262,400
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																																	$ 129,724
August and September 2021 [Member]
Common stock warrant purchase shares | shares																																	1,060,715
Proceeds from issuance of warrants																																	$ 297,000
Exercise price | $ / shares																																	$ 0.60
Warrants are exercisable period																																	3 years
Stock Purchase Agreement [Member]
Common stock to be issued																								$ 52,500
Stock issued during period, shares | shares																								175,000
Warrant Stock Purchase Agreements [Member]
Common stock to be issued																																	$ 402,500
Common stock, shares adjusted | shares																																	519,828
Common stock, value adjusted																																	$ 152,500
Stock issued during period, shares | shares																																	1,234,113
Warrant Stock Purchase Agreements [Member] | Exercise Price of $0.75 [Member]
Number of securities called by Warrants | shares																																175,000	175,000
Warrants, exercise price | $ / shares																																$ 0.75	$ 0.75
Warrant Stock Purchase Agreements [Member] | Exercise Price of $0.80 [Member]
Number of securities called by Warrants | shares																																714,285	714,285
Warrants, exercise price | $ / shares																																$ 0.80	$ 0.80
Stock Purchase Agreements [Member]
Common stock to be issued																										$ 434,000
Stock issued during period, shares | shares																										1,712,500
Convertible Preferred Stock Series C
Options exercised during period, exercise price | $ / shares																																	$ 0.126
Preferred stock, shares issued | shares																																			500,000
Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized | shares																							500,000									500,000	500,000	500,000
Preferred stock, par value per share | $ / shares																																$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares issued | shares																																500,000	500,000	500,000
Number of votes per share | integer																							100
Preferred stock, conversion description																							Each share of Series C Convertible Preferred is convertible into one share of the Company’s common stock.
Third Party [Member]
Stock issued during period, shares, restricted shares | shares																																	2,647,464
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																																	$ 2,117,971
Stock Issued for severence fees, shares | shares							148,166
Stock Issued for severence fees, value							$ 120,000
Accrued interest																																$ 582,707	$ 582,707
Third Party [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares						414,419		141,243																	122,000				65,359		1,176,470
Restricted Stock, Value, Shares Issued Net of Tax Withholdings						$ 76,690		$ 50,000									$ 100,000								$ 50,000				$ 20,000
Stock Issued for severence fees, shares | shares					130,609
Stock Issued for severence fees, value					$ 75,000
Third Party [Member] | S 1 Agreement [Member]
Stock issued during period, shares, restricted shares | shares																																	500,000
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																																	$ 332,500
Actual proceeds																																	228,812
Additional paid in capital																																$ 103,688	$ 103,688
GS Capital [Member]
Stock value for services			$ 57,466
Stock issued during period, shares, issued for services | shares			118,000
MJNA Investment Holdings, LLC [Member] | Series C Convertible Preferred Stock [Member]
Preferred stock, shares issued | shares																						500,000
Proceeds from issuance of preferred stock																						$ 65,000
Third Parties [Member]
Stock issued during period, shares, restricted shares | shares																																	1,114,351
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																																	$ 792,389
Third Parties 4 [Member]
Stock issued during period, shares, restricted shares | shares																											488,428
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																																	$ 291,974
Sapphire Stockholders [Member]
Stock issued during period, shares, restricted shares | shares																	54,000,000
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																	$ 7,506,000
Third Party 1 [Member]
Stock Issued for severence fees, shares | shares							166,686
Stock Issued for severence fees, value							$ 135,000
Third Party 1 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares																													130,719
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																													$ 40,000
Third Party 2 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares																													163,398
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																													$ 50,000
Third Party 3 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares																													326,797	185,185
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																													$ 100,000	$ 25,000
Third Party 4 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares																													816,993	370,370
Restricted Stock, Value, Shares Issued Net of Tax Withholdings																													$ 250,000	$ 50,000
Third Party 5 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares												714,285																	65,359
Restricted Stock, Value, Shares Issued Net of Tax Withholdings												$ 100,000																	$ 20,000
Third Party 6 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares											1,785,714
Restricted Stock, Value, Shares Issued Net of Tax Withholdings											$ 250,000
Third Party 10 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares										250,000
Restricted Stock, Value, Shares Issued Net of Tax Withholdings										$ 35,000
Third Party 8 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares										142,857
Restricted Stock, Value, Shares Issued Net of Tax Withholdings										$ 20,000
Third Party 9 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares										357,153
Restricted Stock, Value, Shares Issued Net of Tax Withholdings										$ 50,000
Third Party 11 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares									200,000	107,143
Restricted Stock, Value, Shares Issued Net of Tax Withholdings									$ 23,630	$ 15,000
Advanced Tear Diagnostics, LLC [Member]
Share issued during period | shares																																	7,000,000
Share issued during perid value																																	$ 4,270,000
Third Party 7 [Member] | Stock Purchase Agreement [Member]
Stock issued during period, shares | shares										5,141,377
Accrued interest										$ 6,414
Conversion Convertible Note Payable										$ 51,414
2020 Transactions [Member]
Common stock to be issued																$ 60,000																		$ 3,309,130
Proceeds from issuance of equity																																		$ 3,309,130
Stock issued during period, shares | shares																190,810																		17,292,751
Stock issued during period, share | shares																286,215
Stock issue during period, value																$ 90,000
2020 Transactions [Member] | Third Party [Member]
Stock issued during period, shares, restricted shares | shares													625,000	2,173,913				62,839	600,000	250,000
Stock issued during period, value, restricted shares													$ 100,000	$ 500,000				$ 25,000	$ 262,500	$ 50,000
Purchase Agreement [Member] | Juniper and Ivy Corporation [Member]
Number of votes per share | integer																					100
Cash payments for purchase of preferred stock																					$ 65,000
Promissory note issued, face value																					$ 435,000
Purhase Agreement [Member] | MJNA Investment Holdings, LLC [Member]
Sale of stock, number of shares issued in transaction | shares																					500,000
Sale of stock, consideration received on transaction																					$ 500,000

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
STOCK OPTIONS AND WARRANTS
Options outstanding, beginning balance	10,300,000	2,000,000
Granted	2,960,715	8,300,000
Exercised	300,000
Expired or canceled	(2,000,000)
Options outstanding, ending balance	10,960,715	10,300,000
Weighted Average Exercise Price, beginning	$ 0.36	$ 0.75
Granted	0.60	0.27
Exercised	0.35	0
Expired or canceled	0.75	0
Weighted Average Exercise Price, ending	$ 0.37	$ 0.36

STOCK OPTIONS AND WARRANTS (D_2

STOCK OPTIONS AND WARRANTS (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
STOCK OPTIONS AND WARRANTS
Weighted Average Exercise Price, beginning	$ 0.36	$ 0.75
Options outstanding, ending balance	10,960,715	10,300,000
Weighted average remaining contractual life	8 years 6 months	9 years 9 months 18 days
Weighted Average Exercise Price, ending	$ 0.37	$ 0.36
Number exercisable number of share	8,094,046	7,466,662
Options Exercisable weighted average exercise price	$ 0.37	$ 0.36

STOCK OPTIONS AND WARRANTS (D_3

STOCK OPTIONS AND WARRANTS (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
STOCK OPTIONS AND WARRANTS
Expected life (years)	10 years	10 years
Risk-free interest rate (%)	1.74%	0.61%
Expected volatility (%)	190.00%	230.00%
Dividend yield (%)	0.00%	0.00%
Weighted average fair value of shares at grant date	$ 1.74	$ 0.61

STOCK OPTIONS AND WARRANTS (D_4

STOCK OPTIONS AND WARRANTS (Details 3) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Options outstanding, beginning balance	10,300,000	2,000,000
Granted	2,960,715	8,300,000
Options outstanding, ending balance	10,960,715	10,300,000
Weighted Average Exercise Price, beginning	$ 0.36	$ 0.75
Granted per share	0.60	0.27
Forfeited/Cancelled per share	0.75	0
Exercised per share	0.35	0
Weighted Average Exercise Price, ending	$ 0.37	$ 0.36
Warrants
Options outstanding, beginning balance	0
Granted	2,850,000
Forfeited/Cancelled	0
Exercised	$ 0
Options outstanding, ending balance	2,850,000	0
Weighted Average Exercise Price, beginning	$ 0
Granted per share	0.71
Forfeited/Cancelled per share	0
Exercised per share	0
Weighted Average Exercise Price, ending	$ 0.71	$ 0

STOCK OPTIONS AND WARRANTS (D_5

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock-based compensation expense	$ 1,143,730	$ 1,947,745
John Huemoeller [Member]
Option issued	2,000,000	2,000,000

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details)	Dec. 31, 2021USD ($)
DISCONTINUED OPERATIONS
Other current assets	$ 5,000
Total current assets	510,017
Intangible assets, net of amortization	47,375
Total asset	562,392
Notes payable	880,000
Accounts payable and accrued expenses	210,640
Due to Canchew	1,526,603
Stock retired	1,857
Total liabilities and equity	2,619,100
Loss on sale of assets	(562,392)
Gain on sale of liabilities	2,619,100
Net gain from sale of assets and liabilities	$ 2,056,708

DISCONTINUED OPERATIONS (Deta_2

DISCONTINUED OPERATIONS (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
DISCONTINUED OPERATIONS
Net sales	$ 0	$ 5,097
Total expenses	(7,996)	(2,016,742)
Gain from sale of asset and liability	0	2,056,708
Other loss (income)	0	(164,356)
(Loss) income from discontinued operations	(7,996)	119,293
Net (loss) income from discontinued operations	(7,996)	119,293
Adjustment of non-cash activities	0	(726,748)
Decrease in accounts receivable	0
Increase in inventory	0
Increase in accounts payable and accrued expenses	0	(1,823,057)
Net cash provided by (used in) operating activities	(7,996)	(1,215,602)
Net cash provided by (used in) investing activities	0	27,490
Net cash provided by (used in) financing activities	$ 0	$ (65,000)

DISCONTINUED OPERATIONS (Deta_3

DISCONTINUED OPERATIONS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
DISCONTINUED OPERATIONS
Recognized Interest Expense	$ 0	$ 0
Purchase price for acquisition	$ 2,609,100

COMMITMENT AND CONTINGENCIES (D

COMMITMENT AND CONTINGENCIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
COMMITMENT AND CONTINGENCIES
Right-of-use assets	$ 76,871	$ 130,722
Lease liability obligations, current	56,871
Lease liability obligations, noncurrent	20,000
Total lease liability obligations	$ 76,871
Weighted-average remaining lease term	1 year 6 months 29 days
Weighted-average discount rate	6.00%

COMMITMENT AND CONTINGENCIES _2

COMMITMENT AND CONTINGENCIES (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
COMMITMENT AND CONTINGENCIES
Operating Lease, Expense	$ 57,684	$ 32,991
Short-term lease expense	15,711	20,831
Total lease expense	$ 73,395	$ 53,822

COMMITMENT AND CONTINGENCIES _3

COMMITMENT AND CONTINGENCIES (Details 2)	Dec. 31, 2021USD ($)
COMMITMENT AND CONTINGENCIES
2022	$ 59,416
2023	20,000
Total minimum payments	79,416
Less: amount representing interest	(2,545)
Total	$ 76,871

COMMITMENT AND CONTINGENCIES _4

COMMITMENT AND CONTINGENCIES (Details Narrative) - USD ($)	Jan. 02, 2019	Dec. 31, 2021	Dec. 31, 2020
Monthly base rent		$ 54,667
Implicit interest rate		5.00%
Monthly base rent		$ 73,395	$ 53,822
Purchase price for acquisition		2,609,100
Research and development expenses		284,869	426,708
John W. Huemoeller [Member]
Increase salary per month	$ 35,000
Common stock granted purchase shares	2,000,000
CFOMember
Increase salary per month	$ 3,000
Sponsored Research Agreement [Member]
Research and development expenses		284,869
Small Business Innovation Research [Member]
Grant income received		279,981
3rd year [Member]
Monthly base rent		$ 5,000
Stock Purchase Agreement [Member]
Salary	$ 10,000
Implicit interest rate		6.00%
Monthly base rent		$ 4,713
Grant income received			$ 115,899
Small business awarded		395,880
Purchase price for acquisition		150,468
Stock Purchase Agreement [Member] | Advanced Tear Diagnostics [Member]
Maintenance costs		$ 11,545

INCOME TAXES (Details)

INCOME TAXES (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Federal Statutory Rate	21.00%	21.00%
State and Local Taxes Rate, Net of federal benefit	6.98%	11.90%
Change in valuation allowance	(28.62%)	32.90%
Prior Year NOL True-Ups	0.64%	0.00%
Effective Tax Rate	0.00%	0.00%
Convertible Preferred Stock Series C
State and Local Taxes Rate, Net of federal benefit	11.90%	11.90%
Change in valuation allowance	(32.90%)	(32.90%)
Effective Tax Rate	0.00%	0.00%
Domestic Tax Authority [Member]
Federal Statutory Rate	21.00%	21.00%

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Net operating loss carry forward	$ 9,722,122	$ 6,038,109
Stock compensation	967,019	646,963
Valuation allowance	11,363,871	6,775,530
Total gross deferred tax assets	0	0
Amortization	608,354	24,082
Interest	66,376	66,376
Convertible Preferred Stock Series C
Valuation allowance	6,327,783
Net deferred tax asset	0
Domestic Tax Authority [Member]
Net operating loss carry forward	$ 6,327,783	6,022,948
Valuation allowance		6,022,948
Net deferred tax asset		$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	12 Months Ended
	Dec. 31, 2021USD ($)
INCOME TAXES
United states tax reform bill description	The U.S. tax reform bill that Congress voted to approve December 20, 2017, also known as the “Tax Cuts and Jobs Act,” made sweeping modification to the Internal Revenue Code, including a much lower corporate tax rate, changes to credits and deductions, and a move to a territorial system for corporations that have overseas earnings. The Act replaced the prior law graduated corporate tax rate, which taxed income over $10 million at 35%, with a flat rate of 21%. The Coronavirus Aid, Relief and Economy Security (CARES) Act (“the CARES Act, H.R. 748”) was signed into law on 27 March 2020. The CARES Act temporarily eliminates the 80% taxable income limitation (as enacted under the Tax Cuts and Jobs Act of 2017) for NOL deductions for 2018-2020 tax years and reinstated NOL carrybacks for the 2018-2020 tax years. Moreover, the CARES Act also temporarily increases the business interest deduction limitations from 30% to 50% of adjusted taxable income for the 2019 and 2020 taxable year. Lastly, the Tax Act technical correction classifies qualified improvement property as 15-year recovery period, allowing the bonus depreciation deduction to be claimed for such property retroactively as if it was included in the Tax Act at the time of enactment. The Company does not anticipate a material impact on its financial statements as of December 31, 2021 due to the recent enactment.
Operating loss carry forward	$ 9,024,000
Expiration date	Dec. 31, 2030
Operating loss carry forward, no expiration period	$ 26,706,957

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Feb. 10, 2022	Jan. 11, 2022	Jan. 06, 2022	May 11, 2015	Mar. 31, 2022	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Debt amount	$ 500,000
Acquisition of common stock shares				5,826,706				10,000
Debt maturity date								Nov. 1, 2026
Convertible debt interest rate							3.50%	3.50%
Option exercised, share								300,000
Accrued interest							$ 16,919	$ 16,919	$ 0
Stock issued for accrued interest, share							500,000
Convertible Preferred Stock Series C
Preferred stock record holder, share			500,000
Preferred stock outstanding, share			500,000
Preferred stock issued, share			500,000
Medical Marijuana Inc [Member]
Ownership percentage								16.40%
Stock Purchase Agreement [Member] | January Thru March 2022 [Member]
Stock issued for cash, share								$ 4,500,000
Stock issued for cash, value								$ 530,228
Subsequent Event [Member]
Debt amount	250,000
Stock issued for cash, share						$ 519,247
Stock issued for cash, value						$ 75,000
Average exercise price						$ 0.315
Acquisition of common stock shares						7,000,000
Common stock issued for prepaid expense, value						$ 100,000
Convertible debt	$ 1,325,000
Debt maturity date	Feb. 10, 2032
Debt interest rate	1.50%
Aggregate face value of convertible debt	$ 1,325,000
Convertible debt interest rate	3.00%
Description of conversion of convertible debt	in whole or in part, at any time by the holder, into restricted shares of the Company’s common stock at a conversion price equal to the lesser of $0.08125 or 70% of the average of the two lowest closing prices of the Company’s common stock in the ten trading days preceding any particular conversion, provided, the holder is prohibited from converting the convertible note, or portion thereof, if such conversion would result in beneficial ownership by the holder and its affiliates of more than 4.999% of Company’s issued and outstanding common stock as of the date of the conversion.
Subsequent Event [Member] | Stock Purchase Agreement [Member]
Stock issued for cash, share					$ 624,290
Aggregate common stock, shares						519,247
Warrants exercisable term						3 years
Common stock issued for prepaid expense, shares						302,115
Option exercised, share		500,000
Common stock issued for settlement of interest due to prepayment of a note, share					173,390
Common stock issued for settlement of interest due to prepayment of a note, value					$ 32,944
Common stock issued in exchange for services, share					500,000
Subsequent Event [Member] | Stock Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Stock issued for cash, value					$ 55,000
Average exercise price		$ 0.126
Aggregate principal amount	$ 1,110,000
Accrued interest	$ 21,875
Stock issued for accrued interest, share	173,390
Common stock issued upon exercise, share		282,759